DESCRIPTION ORNITHINE DERIVATIVES AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS TECHNICAL FIELD This invention relates to new ornithine derivatives and pharmaceutically acceptable salts thereof which are useful as prostaglandin E2 (hereinafter described as PGE2) agonist or antagonist. BACKGROUND ART PGE2 is known as one of the metabolites in an arachidonate cascade. It is also known that PGE2 has various activities such as pain inducing activity, pro-or anti-inflammatory activity, uterine contractile activity, a promoting effect on digestive peristalsis, an awaking activity, a suppressive effect on gastric acid secretion, hypotensive activity, platelet inhibition activity, bone-resorbing activity, angiogenic activity, or the like. PGE2-sensitive receptors have been sub-divided into four subtypes, EPl, EP2, EP3 and EP4, and these receptors have a wide distribution in various tissues. The effects associated with EPl receptor activator are believed to be mediated by mobilization of Ca+4 from intracellular stores. The EP3 receptor is an example of promiscuous receptor that may couple to different second-messenger systems. Further, the effects associated with EP2 and EP4 receptors activator may be considered as inhibitory, and are believed to be associated with a stimulation of adenylate cyclase and an increase in levels of intracellular cyclic AMP. Especially, EP4 receptor may be considered to be associated with smooth muscle relaxation, anti-inflammat ory or pro-inflamma tory activities, 1ympho cyte differentiation, antiallergic activities, kidney dysfunction, mesangial cell relaxation or proliferation, gastric or enteric mucus secretion, or the like. PGE2 receptor blockers, in other words MPGE2 antagonists", possess binding activities to PGE2-sensitive receptors. Accordingly, they possess a PGE2-antagonizing or PGE2-inhibiting activity. Therefore, they are expected as a medicament to treat and prevent PGE2 mediated diseases. Similarly, PGE2 agonists can be medicaments for PGE2 mediated diseases. These PGE2 agonists or antagonists are expected as a medicament to treat and prevent EP4 receptors-mediated diseases, such as kidney dysfunction, inflamma tory conditions, various pains, or the like in human beings o r anima1s . Such PGE2 antagonist is known. For example, in WO 00/16760 and WO 00/18744, oxazole compounds are disclosed. DISCLOSURE OF INVENTION Under the above situation, the inventors of the present invention found that the compounds having an ornithine skeleton or ornithine derivative skeleton bind preferentially to PGE2 receptor, therefore they can be good PGE2 agonists or antagonists, particularly EP4 receptor blockers. As the result, the inventors completed this invention. Accordingly, the present invention relates to novel ornithine derivatives which are useful for treating or preventing PGE2 mediated diseases. One object of this invention is to provide new compound and pharmaceutically acceptable salt thereof as prostaglandin E2 agonists or antagonists. Another object of this invention is to provide a medicament and pharmaceutical composition containing the compound as an active ingredient. A further object of this invention is to provide an agonist or antagonist of PGE2 consisting of the ornithine derivative and a method for treatment and/or prevention of PGE2 mediated diseases which comprises administering an effective amount of the ornithine de ri vat i ve . A further object of the present invention is to provide a use of the ornithine derivative. A further object of the present invention is to provide the compound and pharmaceutica11y acceptable salt thereof which are useful for the manufacture of medicaments for treating or preventing conditions mediated by PGE2/ more particularly useful for treating or preventing kidney dysfunction, inflamma t o ry conditions, various pains, collagen diseases, auto immune diseases, various immun ity diseases, analgesic, thrombosis, allergic disease, cancer and neurodegenerative diseases. A further object of this invention is to provide the comme rcial package comprising the pharmaceutical composition containing the ornithine derivative. The ornithine derivative of this invention can be represented by the following formula (I): (I) wher e i n X is -CO- or - (CH2) k- (wherein k is 1 , 2 or 3); Y is (1) lower alkyl, or (2) Z-(CH2)n-, {whe rein Z is ( 1) aryl, or ( 2 ) R^CO-NR4-( whe rein R1 is (1) aryl, heterocyclyl, aryl- (lower alkyl), aryl- (lower alkoxy), or heterocyclyl- (lower alkoxy) , each of which may be substitut with one or more substituent( selected from the gro consisti ng o f ( a) 1 owe r alkyl, (b) halogen and (c) hydroxy; or (2) lower alkoxy; and R4 is hydrogen, or lower alkyl); and n is 1, 2, 3, 4 , 5 or 6}; R2 is (1) lower alkyl, aryl-(lower alkyl) or (lower alkyl) thio- (lower alkyl), each of which may be substituted with one or more substituent(s) selected from the group consisting of (a) heterocyclyl, (b) carboxy, (c) carboxy- (lower alkyl), (d) amidated carboxy, (e) (lower a 1koxy) carbony1 which may be substituted with cycloalkyl, heterocyclyl or (lower alkanoyl)oxy; and (f) cyano; or (2) aryl which may be substituted with lower alkyl, lower alkenyl, aryl, lower alkoxy, (lower alkyl)amino, (lower alkyl)thio, carboxy, (lower alkoxy)carbonyl, (lower alkoxy)-(lower alkyl), (lower alkyl) amino- (lower alkyl), or (lower alkyl) thio- (lower alkyl), each of which may be further substituted with one or more substituent(s) selected from the group consisting of (a) heterocyclyl, (b) (lower alkoxy)carbonyl, (c) carboxy and (d) amidated carboxy; R3 is (1) -Q-R7, [ whe rein Q is -CO- or -S02- , R7 is (a) lower alkyl which may be substituted with oneormoresubstituent(s) selected fromthe group consisting of cycloa1ky1, aryl which may be further substituted with aryl(s), and he terocyclyl, (b) lower alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of aryl and heterocyclyl, (c) cycloalkyl, (d) aryl which may be substituted with one or moresubstituent(s) selected from the group consisting of 1 owe r a 1ky1, aryl which may be further substituted with hydroxy(s), 1owe r alkoxy, aryloxy, hydroxy, and ha 1ogen, (e) heterocyclyl which may be substituted with one or more substituent (s) selected from the group consisting of 1 owe r a 1ky1, aryl which may be further substituted with halogen (s), and halogen, (f) aryloxy, or (g) amino which may be substituted with aryl (s) which may be further substituted with one or more substituent ( s) selected from the group consisting of aryl and heterocyclyl] ; o r ) lower alkyl which may be substituted with aryl (s) or heterocyclyl(s), each of which may be further substituted with aryl(s) ; and R5 and R6 are independently hydrogen or lower alkyl; or R6 and Y may be linked together to form - ( CH2) m- (wherein m is 2, 3, 4 or 5); or a pharmaceutically acceptable salt thereof. In the above and subsequent description of the present specification, suitable examples of the various definitions to be included within the scope of the invention are explained in detail in the following. The term "lower" is intended to mean a group having 1 to 6 carbon atom(s), unless otherwise provided. Therefore, the "lower alkyl" means a straight or branched chain aliphatic hydrocarbon, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like. It is preferably (C1-C4)alkyl, more preferably (C1-C2)alkyl, most preferably methyl. The "lower alkenyl" means a straight or branched chain aliphatic hydrocarbon having more than one double bond between two carbon atoms, such as ethenyl, 1-methylethenyl, 1-propenyl, 2-propenyl, 1-methyl-l-propenyl, 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, pentenyl, hexenyl, and the like, and it is preferably (C2-C5)alkenyl, more preferably (C2-C3)alkenyl, most preferably ethenyl. The "cycloalkyl" means C3-C10 cycloalkyl group, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, adamantyl, and the like, and it is preferably ( C5-C6) cycloa1ky1. The "aryl" means an aromatic hydrocarbon group, such as phenyl, naphthyl, indenyl, and the like, and it is preferably (C6-C10)aryl, more preferably naphthyl or phenyl, most preferably phenyl. The "heterocyclyl" may include saturated or unsaturated, monocyclic or polycyclic heterocyclic group containing at least one hetero atom selected from nitrogen, sulfur and oxygen atom. The group preferably includes, for example: saturated monocyclic heterocyclic group having 3 to 8-membere containing 1 to 4 nitrogen atom(s) , such as pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, azacycloheptyl, azacyclooctyl, perhydroazepinyl, and the like; monocyclic heteroaryl group containing 1 to 4 nitrogen atom(s), such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, pyrimidinyl, pyrazinyl, dihydropyridazinyl, tetrahydropyridazinyl, triazolyl (e.g., lH-l,2,4-triazolyl, 1H-1,2, 3-triazolyl, 2H-1,2,3-triazolyl, and the like), tetrazolyl (e.g., lH-tetrazolyl, 2H-tetrazolyl, and the like), dihydrotriazinyl (e.g., 4,5-dihydro-l,2,4-triazinyl, 2, 5-dihydro-l, 2,4-triazinyl, and the like); condensated heteroaryl group containing 1 to 5 nitrogen atom(s), such as indolyl, 2,3-dihydroindolyl, isoindolyl, indolyl, 1-methylindolyl, indazolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolinyl, 1,2,3,4-tetrahydroquinolyl, isoquinolyl, benzotriazolyl, tetrazolopyridyl, imidazopyridinyl, methylimidazopyridinyl, tetrazolo-pyridazinyl (e.g., tetrazolo[l,5-b]pyridazinyl, and the like), dihydrotriazolopyridazinyl, quinoxalinyl; monocyclic heteroaryl group having 3 to 8-membere containing 1 to 4 oxygen atom(s) , such as furyl, pyrany1, and the like; condensated heteroaryl group containing 1 to 4 oxygen atom(s), such as benzofurany1, chromenyl, and the like; monocyclic heteroaryl group having 3 to 8-membere containing 1 to 2 sulfur atom(s), such as thienyl, thiepinyl, and the like; condensated heteroaryl group containing 1 to 5 sulfur atom(s), such as benzothienyl, naphto [2, 3 -b ]thienyl, thianthrenyl, benzothienyl, benzothieteyl; saturated monocyclic heterocyclic group having 3 to 8-membere containing 1 to 3 nitrogen atom(s) and 1 to 2 oxygen atom(s) , such as morpholino, and the like; monocyclic heteroaryl group having 3 to 8-membere containing 1 to 3 nitrogen atom(s) and 1 to 2 oxygen atom(s), such as oxazolyl, isoxazolyl, dihydroisoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 2,5-oxadiazolyl, and the like); condensated heteroaryl group containing 1 to 3 nitrogen atom(s) and 1 to 2 oxygen atom(s), such as benzoxazolyl, benzoxadiazolyl, and the like; saturated monocyclic heterocyclic group having 3 to 8-membere containing 1 to 3 nitrogen atom(s) and 1 to 2 sulfur atom(s), such as thiazolidinyl; monocyclic heteroaryl group having 3 to 8-membere containing 1 to 3 nitrogen atom(s) and 1 to 2 sulfur atom(s) , such as thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-thiadiazolyl); condensated monocyclic heteroaryl group containing 1 to 3 nitrogen atom(s) and 1 to 2 sulfur atom(s), such as benzothiazolyl, benzothiadiazolyl, and the like. The "(lower)alkoxy" means a straight or branched chain aliphatic hydrocarbon oxy group, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentoxy, hexoxy, and the like. It is preferably (C1-C4)alkoxy, more preferably (C1-C2)alkoxy. The "(lower alkyl)amino" means a amino group substituted by the above lower alkyl group, such as methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, tert-butylamino, pentylamino, hexylamino, and the like. It is preferably [(C1-C4)alkyl]amino, more preferably [(Cl-C2)alkyl]amino. The "(lower alkyl)thio" means a sulfur atom (II) substituted by the above lower alkyl group, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, tert-butylthio, pentylthio, hexylthio, and the like. It is preferably [(C1-C4)alkyl]thio, more preferably t (C1-C2) alkyl]thio . The "aryloxy" means oxy group substituted with the above aryl, and includes phenyloxy, naphthyloxy, indenyloxy, and the like, and it is preferably phenyloxy. The "halogen" may include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, more preferably a fluorine atom or a chlorine atom, most preferably a chlorine atom. The "amidated carboxy" may include carbamoyl whichmaybe substitutedwith aryl- (lower alkyl) , e.g. , benzyl, phenylethyl, phenylpropy1, or the like. The "(lower alkoxy)carbonyl" means a carbonyl group substituted with lower alkoxy group mentioned above, such as methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, and the like, and it is preferably [ (C1-C4) alkoxy] carbonyl. The "(lower alkanoyl)oxy" means a formyloxy and a (lower a 1kyl) carbonyloxy group such as acetyloxy, propionyloxy, butyryloxy, tert-butyryloxy, isobutyryloxy, valeryloxy, isovaleryloxy, pivaloyloxy, hexanoyloxy, and the like. It is preferably [ (C1-C4) alkanoyl]oxy (including fo rmy1oxy) . The "aryl- (lower alkyl) ", " (lower alkoxy) - (lower alkyl)", "(lower alkyl)amino-(lower alkyl)", "(lower alkyl)thio- (lower alkyl)" and "carboxy- (lower alkyl)" mean the above lower alkyl group substituted with the above aryl, lower alkoxy, (lower alkyl) amino, (lower alkyl)thio and carboxy, respectively. The "aryl-(lower alkoxy)" and "heterocyclyl- (lower alkoxy)" mean the above lower alkyl group substituted with the above aryl and heterocyclyl, respectively. For examp 1e, "aryl- (lower alkoxy)" may include benzyloxy, 1-phenylethoxy, 2-phenylethoxy, 3-phenylpropoxy, 4-phenylbutoxy, naphthylmethoxy, 2-naphthylethoxy, and the like. It is preferably phenyl- (lower alkoxy) , more preferably phenyl [ (C1-C4) alkoxy] , more preferably phenyl[(C1-C2)alkoxy], most preferably benzyloxy. In case where the above groups are substituted, the number of substituentmaybe two ormore if feasible. When the number of substituent is plural, they may be identical or different to each other. In addition, the substituted position is not also limited. For example, when "aryl- (lower alkyl) " is substituted, the substituted position may be aryl moiety or lower alkyl mo i e t y . The Compound (I) contains one or more asymmetric centers and thus they can exist as enantiomers or diastereoisomers. The present invention includes both mixtures and separate individual isomers. However, at the carbon bonded by X, Y and N in Compound (I), (S) isomer is more preferable. The compounds of the formula (I) may also exist in tautomeric forms and this invention includes both mixtures and separate individual tautomers. The Compound (I) and their salt may be in a form of a solvate such as hydrate. Such a solvate is included within the scope of the present invention. Also radiolabelled derivatives of Compound (I) which is suitable for biological studies are included in the scope of the present invention. In the scope of the present invention, the prodrug of the Compound (I) is included, such a prodrug is capable of undergoing metabolic conversion to Compound (I) following administration in body. Further, in the scope of the present invention, metabolites of Compound (I) is included, which metabolites are therapeutically active in the treatment of the targeted medical condition. The compound of the present invention can be converted to salt according to a conventional method. Suitable salt of the compounds (I) is pharmaceutica 11y acceptable conventional non-toxic salts and include an organic acid salt (e.g., acetate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, trifluoroacetate, or the like), an inorganic acid salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, or the like) , a salt with an amino acid (e.g., aspartate, glutamate, or the like), or the like. Preferred embodiments of the Compound (I) is Compound (la) as follows: wherein R2, R7, n and Z are as defined above. More preferred embodiments of the Compound (I) is Compound (lb) as follows: wherein R1 , R2, R7 and n are as defined above. As Compound (lb), the compound having the following definition is more preferable: R1 is aryl- (lower alkoxy); R2 is lower alky, or aryl which may be substituted with carboxy- (lower alkyl); R7 is heterocyclyl which may be substituted with substituted with lower alkyl; and n is 1, 2 , 3 , 4 or 5. In the each definition of the Compound (I), p re f e rab1y, (1) X is -CO-; (2) X is or -(CH2)k- (wherein k is 1 , 2 or 3 ) ; (3) Y is lower alkyl; (4) Y is Z-(CH2)n-f wherein Z is aryl, n is 1, 2, 3, 4 , 5 or 6 ; (5) Y is Z-(CH2)n-/ wherein Z is R^CO-NR4-; wherein R1 is aryl or heterocyclyl, each of which may be substituted with one or more substituent(s) selected from the group consisting of lower alkyl, halogen and hydroxy; R4 is hydrogen; and n is 1 , 2 , 3 , 4, 5 or 6 ; (6) Y is Z-(CH2)n-, wherein Z is R^CO-NR4-; wherein R1 is aryl- (lower alkyl) which may be substituted with one or more s ub s t i t uen t ( s ) selected from the group consisting of lower alkyl, halogen and hydroxy; R4 is hydrogen; and n is 1, 2 , 3 , 4 , 5 or 6; (7) Y is Z-(CH2)n-, wherein Z is R!-CO-NR4-; wherein R1 is aryl- (lower alkoxy) or heterocyclyl- (lower alkoxy), each of which may be substituted with one or more substituent(s) selected from the group consisting of lower alkyl, halogen and hydroxy; R4 is hydrogen; and n is lf 2, 3, 4, 5 or 6; (8) Y is Z - ( C H 2 ) n - , wherein Z is Rx-CO-NR4-; wherein R1 is aryl- (lower alkoxy) which may be substituted with one or more sub s t i t uen t ( s ) selected from the group consisting of lower alkyl, halogen and hydroxy; R4 is hydrogen; and n is 1 , 2, 3, 4, 5 or 6; (9) Y is Z - ( C H 2 ) n - , wherein Z is Ra-CO-NR4-; wherein R1 is phenyl- (lower alkoxy) which may be substituted with one or more sub s t i t uen t ( s ) selected from the group consisting of lower alkyl, halogen and hydroxy; R4 is hydrogen; and n is 4, 5 or 6; (10) Y is Z-(CH2)n-, wherein Z is R^CO-NR4-; wherein R1 is benzyl which may be substituted with one or more substituent ( s) selected from the group consisting of lower alkyl, halogen and hydroxy; R4 is hydrogen; and n is 4 , 5 or 6; (11) R2 is aryl-(lower alkyl) whichmaybe substituted with one or more substituent(s) selected from the group consisting of heterocyclyl, carboxy, carboxy- (lower alkyl), amidated carboxy, (lower alkoxy)carbonyl which may be substituted with cycloalkyl, heterocyclyl or (lower alkanoyl)oxy; and cyano; (12) R2 is aryl which may be substituted with lower alkyl, lower alkenyl, aryl, lower alkoxy, (lower alkyl)amino, (lower alkyl)thio, carboxy, (lower alkoxy) carbonyl, (lower alkoxy) - (lower alkyl) , (lower alkyl)amino- [lower alkyl) or (lower alkyl)thio- (lower alkyl), each of which may be further substituted with one or more subst i-t u e n t ( s ) selected from the group consisting of heterocyclyl, (lower alkoxy)carbonyl, carboxy and amidated carboxy; (13) R2 is aryl which may be substituted with lower alkyl, lower alkenyl, lower alkoxy, (lower alkyl)amino, (lower alkyl)thio, carboxy, (lower alkoxy)carbonyl, (lower alkoxy)-(lower alkyl), (lower alkyl) amino- (lower alkyl) or (lower alkyl) thio- (lower alkyl), each of which may be further substituted with one or more substituent (s) selected from the group consisting of (lower alkoxy)carbonyl, carboxy and carbamoyl; (14) R2 is phenyl which may be substituted with (C1-C4)alkyl, (C2-C4)alkenyl, (C1-C4)alkoxy or (C1-C4) amino, each of which may be further substituted with one or more substituent(s) selected from the group consisting of (lower alkoxy)carbonyl, carboxy and carbamoyl; (15) R2 is phenyl which may be substituted with (Cl-C4)alkyl, (C2-C4)alkenyl or (C1-C4)alkoxy, each of which may be further substituted with carboxy; (16) R3 is -Q-R7, wherein Q is -CO-, R7 is (a) lower alkyl which may be substituted with one or more substituent(s) selected from the group consisting of cycloalkyl, aryl which may be further substituted with aryl(s), and heterocyclyl, (b) lower alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of aryl and heterocyclyl, (c) cycloalkyl, (d) aryl which may be substituted with one or more substituent(s) selected from the group consisting of lower alkyl, aryl which may be further substituted with hydroxy (s) , lower alkoxy, aryloxy, hydroxy, and halogen, (e) heterocyclyl which may be substituted with one or more substituent(s) selected from the group consisting of lower alkyl, aryl which may be further substituted with halogen(s), and halogen, (f) aryloxy, or (g) amino which may be substituted with aryl(s) which may be substituted with one or more substituent ( s ) selected from the group consisting of aryl and heterocyclyl; (17) R3 is -Q-R7, wherein Q is -CO-, R7 is (d) aryl which may be substituted with one or more substituent ( s) selected from the group consisting of lower alkyl, aryl which may be further substituted with hydroxy (s) , lower alkoxy, aryloxy, hydroxy, and halogen, (e) heteroaryl which may be substituted with one or more substituent ( s ) selected from the group consisting of lower alkyl, aryl which may be further substituted with halogen(s), and halogen; (18) R3 is -Q-R7, wherein Q is -CO-, R7 is heteroaryl which may be substituted with one or more substituent(s) selected from the group consisting of lower a1ky1, aryl which may be further substituted with halogen(s), and halogen; (19) R3 is -Q-R7, wherein Q is -CO-, R7 is nitrogen atom containing condensated heteroaryl or nitrogen atom containing monocyclic heteroaryl which may be substituted with one or more substituent(s) selected from the group consisting of lower alkyl and halogen; (20) R3 is -Q-R7, wherein Q is -CO-, R7 is nitrogen atom containing condensated heteroaryl which may be substituted with one or more substituent(s) selected from the group consisting of (C1-C4) alkyl; (21) R3 is -Q-R7, wherein Q is -CO-, R7 is oxygen atom containing condensated heteroaryl or oxygen atom containing monocyclic heteroaryl which may be substituted with one or more substituent(s) selected from the group consisting of lower alkyl and halogen; (22) R3 is -Q-R7, wherein Q is -CO-, R7 is oxygen atom containing condensated heteroaryl which may be substituted with one or more substituent(s) selected from the group consisting of (C1-C4) alkyl; (23) R5 is hydrogen or (C1-C4)alkyl; (24) R5 is hydrogen; (25) R6 is hydrogen or (C1-C4)alkyl; (26) R6 is hydrogen. The Compound (1) is preferably selected from: sodium 6-{ ( 2 S) - 2 - [ (l-benzofuran-2-yl-carbonyl)-amino]-5-[benzyloxycarbonylamino]pentanoylamino}-hexanoate, (2E)-3-{2-[ (2S) -2- [ (lH-indol-2-ylcarbonyl)amino]-5- [benzyloxycarbonylamino]pentanoylamino]phenyl}-acrylic acid, (2E) -3- { 2- [ (2S) -2- [ (l-methyl-lH-indol-2-yl- carbonyl)amino]-5-[benzyloxycarbonylamino]- pentanoylamino]phenyl}acrylic acid, 3-{2-[(2S)-2- [(l-methyl-lH-indol-2-ylcarbonyl)- amino]-5-[benzyloxycarbonylamino]pentanoylamino]- phenyl}propanoic acid, sodium 3 -{2 - [ ( 2 S) -2 -[ (2-quinolinylcarbonyl)amino] 5- [benzyloxycarbonylamino]pentanoylamino]phenyl } -propanoate, 6- [ ( (2S) -2- [ (l-benzofuran-2-ylcarbonyl) amino] - 5 -{[(benzyloxy)carbonyl]amino}pentanoyl)amino]- 2 -naphthoic acid, 3-{2 - [ ( ( 2S) - 5-{ [ (benzyloxy) carbonyl]amino}-2-( [ (8 methylimidazo[1,2 - a]pyridin-2-yl) carbonyl] amino}- pentanoyl)amino]phenylJpropanoic acid, 3- [2- ( { (2S) -5-{ [ (benzyloxy) carbonyl] amino}-2- [ (2-quinolinylmethyl) amino]pentanoyl}amino) - phenyl]propanoic acid, and 3- [2- ( { (2S)-5-{ [ (benzyloxy)carbonyl]amino}-2-[ (IH indol-2-ylcarbonyl)amino]pentanoylJamino)phenyl]- propanoic acid. The processes for preparing Compound (I) of the present invention, especially the typical compounds (la) and (lb) , are explained in the following processes 1-1 to 2. [wherein R1, R2, R3 , R4, R5, R6, R7, Q, X, Y, Z and n are each as defined above; and R2' is (1) lower alkyl, (lower alkyl) thi o- (lower alkyl) or aryl- (lower alkyl); or (2) aryl which may be substituted with lower alkyl, lower alkenyl, aryl, lower a 1koxy, (lower alkyl)amino, (lower alkyl)thio, (lower alkoxy) - (lower alkyl), (lower alkyl)amino- (lower alkyl), or (lower alkyl)thio]-(lower alkyl).] Process 1-1 The compound ( I a -1 ) or its salt can be prepared by the following steps: [step a] reacting the compound (Ila) or its reactive derivative at the carboxy group, or the salt thereof, with the compound (Ilia) or its reactive derivative at the amino group, or the salt thereof to give the compound (IVa) or its salt; and [step b] reacting the obtained compound (IVa) or its salt, with the compound (V) or its reactive derivative at the carboxy group (in case of Q is -CO-) /the sulfo group (in case of Q is -SO2-) , or the salt thereof. [step a] in Process 1-1 In this process, the amine compound (IlIa) can be used on sale or can be synthesized according to general methods obvious to the person skilled in the organic chemistry from commercial compounds. Suitable reactive derivative of the amine compound (IlIa) may include Schif f ' s base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (Ilia) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (Ilia) with a silylating reagent such as N,0-bis(trimethylsilyl)acetamide, N-trimethyl-si1y1 acetamide, or the like. Suitable reactive derivative of the carboxylic acid compound (Ila) may include an acyl halide (carbonyl chloride, carbonyl bromide, and the like.), an acid anhydride, an acid activated amide, an activated ester, or the like. Suitable acid anhydride may be a s ymme trie anhydride or a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid), dialkylphosphorous acid, sulfuric acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid), alkylcarbonic acid, aliphatic carboxylic acid (e.g., pivalic acid, pentanoic acid, isopentanoic acid); aromatic carboxylic acid (e.g., benzoic acid, chlorobenzoic acid, fluorobenzoic acid, nitrobenzoic acid), or the like. Suitable activated amide may be imidazo1y1 amide, 4-substituted imidazolylamide, dimethylpyrazolyl-amide, triazolylamide, tetrazolylamide, or the like. Suitable activated ester may be dime thy 1iminomethy 1 [ (CH3) 2N + = CH-] ester, vinyl ester, propargyl ester, 4-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, methanesulfonylphenyl ester, phenyl thioester, p-nitrophenyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, 8-quinolyl thioester, an activated ester with a N-hydroxy compound (e.g., N,N- dimethylhydroxylamine, l-hydroxy-2H-pyridone, N-hydroxysuccinimide, N-hydroxybenzotrioxazole, N-hydroxyphthalimide,), or the like. When the carboxylic acid compound (Ila) is used in free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of condensing agent. chlo r i de, 2-ethoxy-l- cyanuric Suitable condensing agent may include a carbodiimide [e.g., N,N'-diisopropylcarbodiimide (DIPCI), N,N'-dicyclohexylcarbodiimide (DCC), N-cyclohexyl-N1- (4-diethylaminocyclohexyl) -carbodiimide, N-ethyl-N'- (3-dimethylaminopropyl) -carbodiimide or its hydrochloride], diphenylphosphinic azido, diphenylphosphinic chloride, diethylphosphoryl cyanide, bis (2-oxo-3-oxazolidinyl)phosphinic N,N'-carbonyldiimidoxazole, ethoxycarbonyl-1,2-dihydroquinoline, chloride, or the like. The reactionmay be also carried out in the presence of organic or inorganic base such as alkali metal carbonate, tri (lower)alkylamine, pyridine, N-(lower)alkylmorphorine, or the like. The reaction is usually carried out in a conventional solvent such as water, acetone, alcohol [e.g., methanol, ethanol, isopropyl alcohol, or the like], THF, dioxane, toluene, methylene chloride, chloroform, DMF or any other organic solvents which do not adversely affect the reaction, or the mixture thereof . The reaction temperature is not limited and the reaction is usually carried out under cooling to wa rmi ng. For example, this reaction can be referred to that of Example 27-1 described later. [step b] in Process 1-1 (i) in case where Q is -C0- Suitable reactive derivative of the carboxy compound (V), the condensing agent, base, solvent employable in this process and the reaction temperature are the same as explained above. This reaction can be referred to that of Example 27-3 . (ii) in case where Q is -S02- Suitable reagent to be used in the sulfonylation is, for example, sulfonyl chloride, sulfonic anhydride (e.g., trifluoromethanesulfonic anhydride) or the like. This reaction is preferably carried out in the presence of base. Suitable base may include the inorganic base such as alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide), alkaline earth metal hydroxide (e.g., magnesium hydroxide, calcium hydroxide), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate), alkaline earth metal carbonate (e.g., magnesium carbonate calcium carbonate) or the like ; and the organic base such as tri (lower)alkylamine {e.g., trimethylamine, diisopropylethylamine (DIPEA) }, pyridine, or the like. This reaction is usually carried out in a conventional solvent such as toluene, acetonitrile, benzene, DMF, THF, methylene chloride, ethylene chloride, chloroform, or any other organic solvent which does not adversely affect the reaction. The reaction temperature is not limited and the reaction is usually carried out under cooling to wa rm i ng . Process 1-2 The compound (Ib-1) or its salt can be prepared by the following steps: (i) reacting the compound (lib) or its reactive derivative at the amino group, or the salt thereof, with the compound (Illb) or its reactive derivative at the carboxy group, or the salt thereof to give the compound (IVb) or its salt [step c]; and {i i ) reacting the compound (IVb) or its salt, with the compound (V) or its reactive derivative at the carboxy group (in case of Q is -CO-) /the sulfo group (in case of Q is -S02-) , or the salt thereof [step d]. [step c] in Process 1-2 In this process, the compound (lib) can be obtained in a similar manner to that of [step b] in Process 1-1. This reaction can be referred to that of Example 36-2 described later. [step d] in Process 1-2 In this process, the compound (Ib-1) can be obtained in a similar manner to that of [step b] in Process 1-1. This reaction can be referred to that of Example 27-3 described later. Process 2 In addition, the compound (I) may be obtained on a solid phase support linkage illustrated above. For example, the compound ( I a - 2 ) or its salt can be prepared by the following steps: (i) preparing the resin-bound amine comp ound (I I Ic) [step e]; (ii) reacting the carboxylic acid compound (Ila) or its reactive derivative at the carboxy group, or the salt thereof, with the above resin-bound amine compound (IIIc) or its reactive derivative at the amino group, or the salt thereof to give the amine compound (IVc) or its salt [step f]; (iii) reacting the amine compound (IVc) or its salt, with the compound (V) or its reactive derivative at the carboxy group (in case of Q is -CO-) /the sulfo group (in case of Q is - S 0 2 - ) , or the salt thereof [step g ] ; and (iv) a cleavage reaction of the resin [step h]. [step e] in Process 2 The resin-bound amine compound (IIIc) is coupled to a solid support such as trytyl-resin by treatment with an activating agent, conveniently 4-nitrophenyl chloroformate in the presence of base such as DIPEA in a solvent such as THF, DMF, dichloromethane, or their mi xture . This reaction can be referred to that of Example 1 described later. [step f] and [step g] in Process 2 In these processes, the compounds (IVc) and (Ia-2') can be obtained in a similar manner to that of [step b] in Process 1-1. This reaction can be referred to that of Examples 1 and 27-3 . [step h] in Process 2 Cleavage from the resin is effected, in the case of trytyl resin, by treatment with acid such as trifluoroacetic acid (TFA) as mixture with dichloromethane, or the like. This reaction can be referred to that of Example 1 . Above processes, all starting materials and product compounds may be salts . The compounds of above processes can be converted to salt according to a conventional method. In the above compounds, which have reactive group, may be protected at the group on cue and be deprotected on cue. In these reactions (protecting or deprotecting steps) , concerning the kind of protective group and the condition of the reaction, ^PROTECTIVE GROUPS IN ORGANIC SYNTHESIS Second Edition] T.W.Green and P.G.M.Wuts, John Wiley & Sons, INC. (the contents of which are hereby incorporated by reference) may be referred. The patents, patent applications and publications cited herein are incorporated by reference. For therapeutic purpose, Compound (I) and a pharitiaceutically acceptable salt thereof of the present invention can be used in a form of pharmaceutical preparation containing at least one of said compound as an active ingredient, in admixture with a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can be exemplified by excipient (e.g., sucrose, starch, mannit, sorbit, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate), binding agent (e.g., cellulose, methyl cellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose, starch), disintegrator (e.g., starch, carboxymethyl cellulose, calcium salt of carboxymethyl cellulose, hydroxypropylstarch, sodium glycol-starch, sodium bicarbonate, calcium phosphate, calcium citrate), lubricant (e.g., magnesium stearate, talc, sodium laurylsulfate), flavoring agent (e.g., citric acid, mentol, glycine, orange powders), preservative (e.g., sodium benzoate, sodium bisulfite, methylparaben, propylparaben), stabilizer (e.g., citric acid, sodium citrate, acetic acid), suspending agent (e.g., methyl cellulose, polyvinylpyrrolidone, aluminum stearate, etc.), dispersing agent, aqueous diluting agent (e.g., water), base wax (e.g., cacao butter, polyethylene-glycol, white petrolatum). Such a pharmaceutical composition of the present invention can be used in the form of a pharmaceutical preparation, forexample, in solid, semisolid or liquid form (e.g., tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, solution, emulsion, suspension, or the like), which contains Compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient, suitable for rectal, pulmonary (nasal or buccal inhalation) , nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation. The pharmaceutical preparations of the present invention may be capsules, tablets, dragees, granules, inhalant, suppositories, solution, lotion, suspension, emulsion, ointment, gel, cream, orthelike. If desired, there may be included in these preparations, auxiliary substances, stabilizing agents, wetting or emulsifying agents, buffers and other commonly used addi t i ve s . While the dosage of therapeutically effective amount of the Compound (I) depend upon the age and condition of each individual patient, an average single dose of about 0.01 mg, 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the Compound (I) may be effective for treating the above-mentioned diseases. In general, amounts between 0.01 mg/kg and about 50 mg/kg, 1 to 4 times per day may be administered. This application is based on Australian Patent Application No.2003907110 filed on December 22, 2003, the contents of which are hereby incorporated by references. Although the present invention has been fully described by way of example, it is to be understood that various changes andmodifications will be apparent to those skilled in the art. Therefore, unless otherwise such changes and modifications depart from the scope of the present invention hereinafter defined, they should be construed as being included therein. THE BEST MODE FOR CARRYING OUT THE INVENTION The following Examples are given only for the purpose of illustrating the present invention in more de tail. Although the present invention has been fully described by way of example, it is to be understood that various changes andmodifications will be apparent to those skilled in the art. Therefore, unless such changes and modifications depart from the objective of the present invention, they should be construed as being included therein. Abbreviations used in this application are as follows: EtOAc: ethyl acetate DMF: N,N-dimethylformamide Boc: tert-butoxycarbonyl Fmoc: 9-fluorenylmethoxycarbonyl WSCD: 1- (3-dimethylaminopropyl)-3-ethyl- carbodiimide hydrochloride DIPCI : 1, 3-diisopropylcarbodiimide TBTU: O~benzotriazole-N,N,N,N'-tetramethyl- uronium-hexafluorophosphate HOBT: 1-hydroxybenzotriazole THF: tetrahydrofuran DIPEA: N,N-diisopropylethylamine EtOH: ethanol Me OH: methano1 NMP: l-methyl-2-pyrrolidinone BSA: N,0-bis (trimethylsilyl)acetamide PyBOP: benzotriazole-1-yl-oxy-tris-pyrrolidino- phosphonium hexafluorophosphate DIEA: N/N-diisopropylethylamine DMSO: dimethyl sulfoxide DEAD: diethyl azodicarboxylate DCM: dichloromethane Et20: diethyl ether PyBroP: bromo-tris-pyrrolidino-phosphonium hexafluorophosphate TFA: trifluoroacetic acid MSNT: 1- (mesitylene-3-sulfonyl) -3-nitro-lH- 1,2,4-triazole Et20: diethyl ether Ac20: acetic anhydride HATU: 0-(7-azabenzotriazol-l-yl)-l, 1,3,3- tetramethyluronium hexafluorophosphate TISH: triisopropylsilane Fmoc: 9-fluorenylmethoxycarbonyl Mtt: (4-methyl)trityl HPLC: high performance liquid chromatography Ex amp 1e 1 6- { (2S)-2-[ (l-Benzofuran-2-ylcarbonyl)amino]-5- [benzyloxycarbonylamino]pentanoylamino}hexanoic acid A solution of 6-[9-(flouorenylmethoxycarbonyl)-amino]hexanoic acid (18 0 mg) and DIPEA ( 0 . 1 2mL) in dich1oromethane (3mL) was added to a reaction vessel containing Cl-trytyl resin (200mg, 1. 3mmo1/g, loading) . After the vessel was shaken for 12 hours at room temperature, the resin was washed successively with dichloromethane, THF, DMF and dichloromethane. After cleavage of Fmoc by using 20% piperazine in DMF (5mL), 2-Fmo c-5 - [benzyloxycarbonylamino] -pentanoicacid (254mg), TBTU ( 17 Omg) , HOBT (70mg) and DIPEA ( 0 . 18mL) were added to a solution of the obtained resin in DMF (3mL). After the vessel was shaken for 12 hours at room temperature, the resin was washed successively with dichloromethane, THF, DMF and dichloromethane. After cleavage 9- (flouorenylmethoxy carbonyl)amide by using 20% piperazine in DMF (5mL), benzofuran-2 -carboxy1ic acid (210mg), DIPCI (0.21mL) and DIPEA ( 0.2 3mL) were added successively to a solution of the obtained resin in dichloromethane ( 3mL ) After the vessel was shaken for 12 hours at room temperature, the resin was washed successively with dichloromethane, THF, DMF, and dichloromethane. Cleavage from the resin was performed with 1% trifluoromethanesulfonic acid in dichloromethane (5mL) for 10 minutes at room temperature. After the filtrated solvent was evaporated under pressure, the residue was washed with ether to give the target compound (lOOmg, 72%). MS 524 (M+l). Example 2 { ( 2 S) -2- [ (l-Benzofuran-2-ylcarbonyl) amino] - 5 - [benzyloxycarbonylamino]pentanoylamino}acetic acid The target compound was obtained in a similar manner to that of Example 1. MS : 4 68 (M+l). Example 3 4-{ ( 2S) -2- [ (l-Benzofuran-2-ylcarbonyl)amino]-5- [benzyloxycarbonylamino]pentanoylamino}butanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 4 96 (M + l) . Examp1e 4 5 -{ (2 S) - 2 - [ (l-Benzofuran-2-ylcarbonyl)amino]-5- [benzyloxycarbonylamino]pentanoylamino}pentanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 510 (M+l). Ex ample 5 7- { ( 2 S)-2- [ (l-Benzofuran-2-ylcarbonyl)amino]-5- [benzyloxycarbonylamino]pentanoylamino}heptanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 538 (M+l). Ex amp 1e 6 6- { ( 2 S) -2- [ (l-Benzofuran-2-ylcarbonyl) amino] -3 -[benzyloxycarbonylamino]propanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS 496 (M+l). Examp le 7 6- { (2 S ) -2 -[ (l-Benzofuran-2-ylcarbonyl) amino]-4- [benzyloxycarbonylamino]butanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS 510 (M+l). Examp1e 8 6~{ (2S) -2- [ (l-Benzofuran-2-ylcarbonyl) amino] - 6- [benzyloxycarbonylamino]hexanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS 538 (M+l ) . Examp1e 9 6-{(2R) -2 - [(l-Benzofuran-2-ylcarbonyl)amino]-6- [benzyloxycarbonylamino]hexanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 538 (M+l). Examp1e 10 6 -{ ( 2 S) - 2 - [ (l-Benzofuran-2-ylcarbonyl)amino]-3- phenylpropanoylaminojhexanoic acid The target compound was obtained in a similar manner to that of Example 1 . MS : 423 (M+l). Examp1e 11 6-{ ( 2 S ) - 2 - [ (l-Benzofuran-2-ylcarbonyl)amino]-3- methylbutanoylaminojhexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 375 (M+l). Ex amp1e 12 6- [ ( 2S) -1- (l-Benzofuran-2-ylcarbonyl) -2- (pyrrolidinyl)carbonylamino]hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 373 (M+l). Examp1e 13 6- { { 2 S) - 2 - [ (l-Benzofuran-2-ylcarbonyl)amino]-5- [ethoxycarbonylamino]pentanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 47 6 (M+l). Ex amp 1e 14 6- { (2S) -2- [ (l-Benzofuran-2-ylcarbonyl) amino]- 5 - [benzoylamino]pentanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 494 (M+l). Example 15 6-{ (2S)~2,5-Bis[ (1-benzofuran-2-ylcarbonyl)amino] - pentanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 534 (M+l). Ex amp1e 16 6-{ (2 S) -2 - [ (l-Benzothien-2-ylcarbonyl) amino] -5- [benzyloxycarbonylamino]pentanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 54 0 (M+l). Ex ample 17 6- { ( 2 S) -2- [ (2E) - (3-Phenyl-2-propenoyl) amino] ~5- [benzyloxycarbonylamino]pentanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 510 (M+l). Examp1e 18 6- { (2 S) -2 - [ (4-Biphenylylcarbonyl) amino]-5- [benzyl- oxycarbonylamino]pentanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 560 (M+l). Examp1e 19 6- { ( 2S) -2- [ (2-Naphthoyl) amino] -5- [benzyloxycarbonylamino] pentanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 534 (M+ 1 ) . Examp1e 2 0 6- { (2S)-2~[ (lH-Indol-2-ylcarbonyl)amino]-5- [benzyloxycarbonylamino]pentanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS : 52 3 (M+1). Examp1e 2 1 6-{ (2S) -2- [ (lH-Indol-3-ylcarbonyl)-amino]-5- [benzyloxycarbonylamino]pentanoylamino}-hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS 523 (M+l). Example 22 6-{ (2S)-2-[ (lH-Indol-6-ylcarbonyl)amino]-5- [benzyloxycarbonylamino]pentanoylamino}hexanoic acid The target compound was obtained in a similar manner to that of Example 1. MS 523 (M+l). Examp1e 2 3 Sodium 6 - { ( 2 S) - 2 - [ (l-benzofuran-2-yl-carbonyl)- amino] -5- [benzyloxycarbonylamino]pentanoylamino}- hexanoate To a solution of 6-{(2S)-2-[(l-benzofuran-2-yl-carbonyl) amino]-5- [benzyloxycarbonylamino] -pentanoylamino}hexanoic acid (50mg) obtained in Example 1 in MeOH , was added IN NaOH (O.lmL) at room temperature. After the solvent was evaporated under pressure, the residue was washed with ether to give the target compound (50mg). MS : 52 4 (M+1). 1H-NMR (200MHz, DMSO-d6) : 5 1.2-1.8(10H, m), 1.95(2H, t, J=7.0Hz) , 3 . 03 ( 4H, t , J=6.2Hz) , 4 . 43 ( 1H, m), 4 . 99 ( 2H s ) , 7 . 2-7 . 6 ( 8H, m) , 7.6-7.9(3H, m) , 8 . 31 ( 1H, t , J=5.4Hz), 8 . 87 ( 1H d, J=8.2Hz). Example 2 4 Benzyl N-{ ( 4 S) - 4 - [ (l-benzofuran-2-yl-carbonyl)-amino]-5-oxo-5-[(6-oxo-6-benzylaminohexyl)amino]-pentyl}carbamate To a solution of 6-{ (2S) -2 - [ (l-benzofuran-2-ylcarbonyl) amino] -5- [benzyloxycarbonylamino] -pentanoylamino}hexanoic acid (50mg) obtained in Ex amp le 1 in DMF (lmL), were added successively TBTU (8 4mg) , HOBT (18mg), DIPEA ( 0. 02 3mL) and benzylamine ( 0 . 0 1 4 m L ) at room temperature. After stirring for 4 hours, the mixture was diluted with EtOAc. The solution was washed successively with water, IN HC1, IN NaOH and brine, and dried over MgS04. After the filtrated solvent was evaporated under pressure, the residue was washed with ether to give the target compound (40mg). MS 613 (M + l) . Examp1e 2 5 Benzyl N-{ ( 4 S) - 4 - [ (l-benzofuran-2-ylcarbonyl)-amino] -5-oxo-5- [6-oxo-6- [ (2-phenylethylamino-hexyl) aminojpentyl] carbamate The target compound was obtained in a similar manner to that of Example 24. MS : 62 7 (M+l). Examp1e 2 6 Benzyl N-{ ( 4 S) -4- [ (l-benzofuran-2-ylcarbonyl)-amino]-5-oxo-5-[6-oxo-6-[(3-phenylpropylamino-hexyl)amino]pentyl]carbamate The target compound was obtained in a similar manner to that of Example 24. MS 641 (M+l). Example 27-1 Methyl ( 2E) -3-{2- [ ( 2S) -5- [benzyloxycarbonylamino] 2- [tert-butoxycarbonylamino]pentanoylamino] -phenyl }acrylate To a solution of (2S) - 2 - (tert-butoxycarbonylamino) -5- (benzyloxycarbonylamino) -pentanoic acid (6.00g) and methyl (2E) -3- (2-aminophenyl) acrylate ( 3 . 77g ) in DMF (60ml), were added successively HOBT (3.32g), WSCD (6.28g) and 4 - (dimethy1 ami no)pyridine (400mg) . The mixture was stirred at 50^ for 15 hours. After cooling to room temperature, the mixture was quenched by the addition of water (120mL) and extracted with EtOAc (120mL). The extract was washed successively with water ( 12 OmL) , saturated aqueous sodium hydrogencarbonate ( 1 2 OmL) / IN HC1 {12 OmL) , water (120mL) and brine ( 1 2 OmL ) , and dried over MgS04. Filtration followed by evaporation gave a crude product which was chromatographed on silica gel (eluent: hexane/EtOAc=1/1) to give the target compound (2.58g) as a yellow crystalline solid. MS ( ( + ) ESI) m/z : 548 (M + Na) + . Example 2 7-2 Methyl (2E)-3-{2-[ (2S)-2-amino-5-[benzyloxy- carbonylamino]pentanoylamino]phenyl}acrylate hydro ch1o r i de To a suspension of methyl (2E)-3-{2-[(2S)-2-[tert-butoxycarbonylamino]-5-[benzyloxycarbonylamino]pentanoylamino]phenyl}- acrylate (2.58g) obtained in Example 27-1 in EtOAc (20mL) , was added 4N hydrogen chloride in EtOAc (20mL) . The mixture was stirred at room temperature for 1 hour. The solvent was removed by evaporation to give the target compound (2.40g) as a yellow solid. MS ( ( + )ESI) m/z : 426 (M + H)+, 448 (M+Na)+. Ex amp1e 2 7-3 Methyl (2E)-3-{2-[ (2S)-2-[ (lH-indol-2-ylcarbonyl)-amino]-5-[benzyloxycarbonylamino]pentanoylamino]-phenyl}acrylate To a solution of methyl (2E) -3-{2- [ (2S) -2-amino-5- [benzyloxycarbonylamino] pentanoylamino]phenyl}acrylate hydrochloride (400mg) obtained in Example 27-2 in DMF (4.0mL), were added successively indo1e- 2 -carboxy1ic acid (154mg), HOBT ( 17 6mg ) and WSCD (0.32mL). The mixture was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc (lOmL) and washed with water (1OmL X 2 ) . The organic layer was stirred vigorously at room temperature for 1 hour. The precipitates were collected by filtration, washed with EtOAc (lmL><2), and dried under reduced pressure to give the target compound (115mg) as a white solid. MS ( { + ) ESI) m/z : 591 (M+Na)+. Ex amp 1e 2 8 (2E)-3-{2-[ (2S) -2- [ (lH-Indol-2-ylcarbonyl) amino]-5- [benzyloxycarbonylamino]pentanoylamino]phenyl}-acrylic acid To a suspension of methyl (2E) -3-{2- [ ( 2S) -2- [ (lH-indol-2-ylcarbonyl) amino] -5- [benzyloxycarbonylamino]pentanoylamino]phenyl}-acrylate ( 10 9mg) obtained in Example 27-3 in MeOH (2.0mL) and THF (2.0mL) , was added IN NaOH (0.38mL). The mixture was refluxed for 2 hours. After cooling to room temperature, the mixture was quenched by the addition of IN HCl (20mL) and extracted with EtOAc (20mL) . The extract was washed with water (20mL) and brine (20mL), and dried over MgS04. Filtration followed by evaporation gave the target compound (102mg) as a pale yellow solid. MS ( (-)ESI) m/z : 553 (M-H)~. aH-NMR (200MHz, DMSO-d6) : 8 1.61-1.99(4H, m), 3.05-3.11 (2H, m), 4.63-4.79{lH, m) , 5 . 01 (2H, s), 6. 49 ( 1H, d, J=15.9Hz), 7.00-7.83(16H, m), 8 . 61 ( 1H, d, J=7.7Hz), 1 0 . 0 ( 1H, br-s), 1 1 . 6 ( 1H, br-s),12.9(lH, br-s). Example 2 9 Methyl (2E)-3-{2-[ (2S) -2- [ (l-methyl-lH-indol-2-yl-carbonyl)amino]-5-[benzyloxycarbonylamino]-pentanoylamino]phenyl}acrylate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 605(M+Na)+. Ex amp 1e 3 0 (2E) -3-{2- [ (2S) -2- [ (l-Methyl-lH-indol-2-yl-carbonyl)amino]-5-[benzyloxycarbonylamino]-pentanoylamino]phenyl}acrylic acid The target compound was obtained in a similar manner to that of Example 28. MS ( ( -) ESI) m/z : 567 (M-H) '. aH-NMR (200MHz, DMSO-d6) : 6 1.61-1.99(4H, m) , 3.09-3.11 (2H, m) , 3.99(3H, s ) , 4.60-4.71(lH, m) , 5 . 01 (2H, s) , 6. 49 (1H, d , J=l5.9Hz), 7.07-7.84(16H,m), 8.62(1H, d, J=7.7Hz)/ 9.97(1H, br-s), 12.4(1H, br-s). Examp1e 3 1 Methyl ( 2E ) -3- { 2- [ (2S)-2-[ (4-biphenylylcarbonyl) -amino] -5- [benzyloxycarbonylamino]pentanoylamino] -phenyl}acrylate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 628 (M+Na)4. Ex amp1e 3 2 (2E) -3-{2- [ ( 2S) -2- [ (4-Biphenylylcarbonyl) amino] [benzyloxycarbonylamino]pentanoylamino]phenyl}-acrylic acid -5- The target compound was obtained in a similar manner to that of Example 28, MS ( (-)ESI) m/z : 590 (M-H)~. aH-NMR (200MHz, DMSO~d6) : 5 1.60-1.99(4H, m) , 3.08-3.11(2H, m) , 4.64-4.79(lH, m) , 5.01 (2H,s) , 6. 48 ( 1H, d, J=15. 9Hz) , 7.19-7.54(12H/ m) , 7.73-7.83(6H, m) , 8.04(2H, d, J=8.4Hz), 8 . 66 ( 1H, d, J=7. 5Hz) , 9. 97 ( 1H, br-s), 12 . 4 ( 1H, br-s) . Example 3 3 Methyl (2E)-3-{2-[(2S)-2-[(l-benzofuran-2 carbonyl) amino]-5- [benzyloxycarbonylamino] -pentanoylamino]phenyl}acrylate yl- The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 592 (M + Na)4. Examp1e 3 4-1 Methyl 3-{2- [ (2S) -2- [ (l-benzofuran-2-ylcarbonyl) - amino]-5-[aminopentanoylamino]phenyl(propanoate To a solution of methyl ( 2E) - 3-{2 - [ ( 2S) -2- [ (l-benzofuran-2-ylcarbonyl) amino] -5- [benzyloxycarbonylamino] pentanoylamino]phenyl}acrylate (1.30g) obtained in Example 33 in MeOH (26mL) and THF (26mL), was added 10% palladium on activated carbon (50% wet, 1 3 Omg ) . The mixture was hydrogenated (latm) at room temperature for 90 minutes. The catalyst was removed by filtration through a Celite cake and washed with MeOH. The filtrate was concentrated in vacuo to give the target compound (1.19g) as a white solid. Example 34-2 Methyl 3-{2 - [ (2S) -2- [ (l-benzofuran-2-ylcarbonyl) - amino] -5- [benzyloxycarbonylamino] pentanoylamino] - phenyl}propanoate To a solution of methyl 3 - { 2 - [ ( 2 S ) -2- [ (l-benzofuran-2-ylcarbonyl) amino] - 5 -aminopentanoylamino]phenyl}propanoate ( 1 . 0 5 g ) obtained in Example 34-1 in THF (lOmL) andwater (lOmL), was added benzyl chloroformate (0.38mL) at 5"C while the pH was adjusted to 8.0-9.0 by the addition of 10% aqueou s NaOH. After stirring at the same temperature for 30 minutes, the mixture was extracted with EtOAc (20mL). The extract was washed with water (20mL) and brine (20mL), and dried over MgS04. Filtration followed by evaporation gave a crude solid which was purified by silica gel chromatography (eluent: hexane/EtOAc=l/l) and recycling preparative HPLC equipped with a gel permeation chromatography column (eluent: chloroform) to give the target compound (572mg) as a white crystalline solid. MS ( ( + ) ESI) m/z : 594 (M + Na) + . Examp1e 3 5 3- {2- [ (2S)-2-[ (l-Benzofuran-2-ylcarbonyl) amino] [benzyloxycarbonylamino]pentanoylamino]phenyl}- propanoic acid -5- The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 556 (M-H) ~ . 2H-NMR (200MHz, DMSO-d6) : 6 1.57-1.99(4H, m), 2.45-2.51 (2H, m) , 2.78-2. 85<2H, m), 3.06-3.09(2H, m) , 4.65-4.68(lH, m) , 5. 00 ( 2H, s ) , 7.11-7.52 (12H, m) , 7.66-7.81(3H/ m) , 8 . 75 ( 1H, d, J = 7.7Hz), 9 . 62 ( 1H, br-s), 12 . 2 ( 1H, br-s) . Ex amp1e 3 6-1 Methyl (2E)-3-{2-[(2S)-2-[tert-butoxycarbonyl- amino]-5-amino-pentanoylamino]phenyljpropanoate The target compound was obtained in a similar manner to that of Example 34-1. MS ( ( + )ESI ) m/z : 394 (M+H)+. Examp1e 3 6-2 Methyl 3-{2- [ (2S) -2- [tert-butoxycarbonylamino] -5-[(2-chlorobenzyloxycarbonyl)amino]pentanoylamino]-phenyl}propanoate To a solution of methyl (2E) -3-{2- [ (2S) -2- [tert-butoxycarbonylamino] -5-aminopentanoylamino]phenyl}propanoate (4 . 3 4 g) obtained in Example 36-1 in dich1oromethane (80mL), was added triethy1 amine (2.31mL) . The solution was cooled to 5*C , To the solution was added 2 -ch1 orobenzy1 ch1oroformate (1.86mL) at 5, and the mixture was stirred at the same temperature for 1 hour. The solvent was removed by evaporation, and the residue was partitioned between IN HCl (80mL) and EtOAc (BOmL). The organic layer was separated, washed successively with water (80mL), saturated aqueous sodiumhydrogencarbonate (80mL) and brine (BOmL) , and dried over MgS04. Filtration followed by evaporation gave a yellow solid which was chromatographed on silica gel (eluent:hexane/EtOAc~2/lto3/2) to give the target compound ( 3 . 6 2 g ) as a white solid. MS ( ( + ) ESI) m/z : 584 (M + Na) Examp1e 3 6-3 Methyl 3-{2-[ (2S)-2-amino-5-[ (2-chlorobenzyloxy- carbonyl)amino]pentanoylamino]phenyl}propanoate hydrochloride To a suspension of methyl 3 - { 2 - [ ( 2 S ) - 2 -[tert-butoxycarbonylamino] -5- [ (2-chlorobenzyloxy-carbonyl)amino]pentanoylamino]phenyl}propanoate (3 . 4 5 g) obtained in Example 36-2 in EtOAc (15mL), was added 4N hydrogen chloride in EtOAc ( 4 5 m L) . The mixture was stirred at room temperature for 1 hour. The mixture was concentrated in vacuo to give the target compound (3.11g) as a pale yellow viscous oil. MS ( ( + )ESI) m/z : 462 (M+H)+. Ex amp 1e 3 6-4 Methyl 3- { 2- [ (2S) -2- [ (l-benzofuran-2-yl-carbonyl) -amino] -5-[ (2-chlorobenzyloxycarbonyl) amino] -pentanoylamino}phenyl]propanoate The target compound was obtained in a similar manner to that of Example 27-3. Examp1e 3 7 3- {2- [ ( 2S) -2- [ (l-Benzofuran-2-yl-carbonyl) amino]-5 - [ (2-chlorobenzyloxycarbonyl) amino]pentanoylamino] phenyl] propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 590 (M-H) 2H-NMR (2 00MHz, DMSO-d6) 8 1 . 59-1 . 99 (4H, m) , 2.45-2.50(2H,m), 2.78-2.85(2H,m), 3.07-3.10 (2H, m) , 4.66-4.69(lH, m) , 5. 09 (2H, s ) , 7.11-7.52 (11H, m),7.66-7.81(3H, m) , 8 . 7 4 (1H, d, J = 7 . 6Hz) , 9.61 ( 1H, br-s ) f 12. 1 (1H, br-s). Examp1e 3 8-1 Methyl 3 -{2 - [ (2 S) -2- [tert-butoxycarbonylamino] -5-[ (benzyloxycarbonyl) amino]pentanoylamino]phenyl}-pr opanoat e The target compound was obtained in a similar manner to that of Example 36-2. MS ( ( + ) ESI) m/z : 550 (M + Na) + . Examp1e 3 8-2 Methyl 3 - { 2 - [ (2S)-2-amino-5-[benzyloxycarbonyl- amino]pentanoylamino]phenyl}propanoate hydrochloride The target compound was obtained in a similar manner to that of Example 36-3. MS ( ( + ) ESI) m/z : 428 (M + H) + . Ex amp 1e 3 8-3 Methyl 3- { 2- I (2S)-2-[ (l-methyl-lH-indol-2-yl-carbonyl)amino]-5-[benzyloxycarbonylamino]-pentanoylamino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 607 (M + Na) + . Examp1e 3 9 3-{2 - [ (2S) -2- [ (l-Methyl-lH-indol-2-ylcarbonyl) -amino]-5-[benzyloxycarbonylamino]pentanoylamino]-phenyljpropanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 569 (M-H)". XH-NMR (200MHz, DMSO-d6) : 6 1.59-1.91 (4H, m) 2.48-2.54(2H,m), 2.79-2.87 (2H, m) , 3.05-3.10(2H, m) 3.98(3H, s ) , 4.55-4.66(lH, m) , 5. 01 ( 2H, s) 7.07-7.35(13H, m), 7.53(1H, d, J=8.3Hz), 7.65(1H, d J=7.9Hz), 8.62(1H, d, J=7.6Hz)/ 9.56<1H, br-s) 12.1(1H, br-s) . Ex amp 1e 4 0 Methyl 3-{2-[ (2S) -2- [ (2-quinolinylcarbonyl) -amino] -5- [benzyloxycarbonylamino]pentanoylamino] -phenyl}propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) ra/z : 605 (M + Na) + . Examp1e 4 1 Sodium 3- {2- [ (2 S) -2- [ (2-quinolinylcarbonyl) amino] -5-[benzyloxycarbonylamino]pentanoylamino]phenyl}-pr opano ate To a suspension of methyl 3 -{2 - [ (2 S) -2- [ (2-quinolinylcarbonyl) amino] -5-[benzyloxycarbonylamino]pentanoylamino] -phenyl } - propanoate (lOOmg) obtained in Example 40 in EtOH ( 2 . OmL) , was added IN NaOH (0 . 34 3mL) . The mixture was refluxed for 10 minutes. The resulting solution was allowed to cool to room temperature, stirred for 16 hours, and concentrated in vacuo. The residual solid was dissolved in EtOH (2.OmL) and the solution was stirred at room temperature for 2 hours. The resulting precipitates were collected by filtration, washed with EtOH, and dried under reduced pressure at 60^ to give the target compound (79.3mg) as a white solid. MS ( (-)ESI) m/z : 567 ( M-Na) " . 2H-NMR (200MHz, DMSO-d6) : 5 1 . 55 -1 . 58 (2H, m) 1.95-2.06(2H, m), 2.27-2.30(2H, m) , 2.73-2.74 (2H, m) 3.12-3.14 (2H, m) , 4.86-4.88(lH, m), 4.98(2H, s) 7.00-7.32(8H, m), 7.70-7.90(4H, m), 8 . 1 1 ( 1H, d J=8.1Hz), 8.21(2H, d, J=8.5Hz), 8.61(1H, d, J=8.5Hz) 9.01(1H, d, J=8.4Hz), 13 . 1 ( 1H, br-s). Example 4 2-1 Methyl 4 - [2 - ( { (2S)-5-{ [benzyloxy) carbonyl]amino}-2-[(tert-butoxycarbonyl)amino]pentanoyl}amino)-ethyl]benzoate To a suspension of (2S)-5-[[(benzyloxy)-carbonyl]amino]-2-[(tert-butoxycarbonyl)amino]-pentanoic acid (l.OOg) and methyl 4-(2-aminoethyl)benzoate hydrochloride (647mg) in N,N-dimethylformamide ( 2 0mL) , were added HOBT (3.32g), and WSCD (553 mg) at room temperature. The mixture was stirred for 2 hours, The mixture was quenched by the addition of water (40mL) a nd extracted with ethyl acetate (40mLXi) . The extract was washed with water (40mLX2), saturated aqueous sodium hydrogencarbonate (40mLX 1) and brine (4 OmL X i ) , and then dried over magnesium sulfate. Filtration followed by evaporation gave the target compound (1.45g) as a pale yellow solid. MS ((+)ESI) m/z : 550 (M+Na)+. Example 42-2 Methyl 4-{2-[((2S)-2-amino-5-{[(benzyloxy)- carbonyl]aminoJpentanoyl)amino]ethylJbenzoate hydrochloride Methyl 4 - [2 - [ f (2 S) - 5 - [ [ (benzyloxy) carbonyl] -amino] -2- [ (tert-butoxycarbonyl) amino]pentanoyl] -amino]ethyl]benzoate (1.43 g) obtained in Example 42-1 was suspended in 2.5N hydrogen chloride in methanol ( 1 4mL ) . The mixture was stirred at room temperature for 16 hours. The solvent was removed by evaporation to give the target compound (1.27g) as a yellow solid. MS ( ( + ) ESI) m/z : 450 (M + Na) + . Example 4 2-3 Methyl 4-{2 - [ ( ( 2S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino] - 5 -{ [ (benzyloxy) carbonyl]aminojpentanoyl) -amino]ethylJbenzoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 594 (M+Na)+. Examp1e 4 3 4 -{2 - [ ( (2S) -2- [ (l-Benzofuran-2-ylcarbonyl) amino] -5-{[(benzyloxy)carbonyl]aminojpentanoyl)amino]-ethyljbenzoic acid The target compound was obtained in a similar manner to that of Example 2 8. MS ( (-)ESI) m/z : 556 (M-H) ". Examp1e 4 4-1 Methyl 6- ( { ( 2 S) - 5 -{ [ (benzyloxy) carbonyl]amino} [ (tert-butoxycarbonyl)amino]pentanoyl}amino) - 2 -naphthoa t e -2- The target compound was obtained in a similar manner to that of Example 42-1. MS ({+)ESI) m/z : 572 (M+Na)+. Example 4 4-2 Methyl 6 - [ ( (2S)-2-amino-5-{ [ (benzyloxy) carbonyl] - amino}pentanoyl)amino]-2-naphthoate hydrochloride The target compound was obtained in a similar manner to that of Example 27-2. MS ( ( + ) ESI) m/z : 450 (M + H)4. Example 4 4-3 Methyl 6- [ ( ( 2S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino] - 5 -{ [ (benzyloxy) carbonyl] amino}pentanoyl)-amino]-2-naphthoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 616 (M+Na)+. Examp1e 4 5 6- [ ( ( 2 S) -2- [ (l-Benzofuran-2-ylcarbonyl) amino] - 5 -{ [ (benzyloxy) carbonyl] aminojpentanoyl) amino] - 2 -naphtho i c acid The target compound was obtained in a similar manner to that of Example 28. MS ((-)ESI) m/z : 578 (M-H)'. ^-NMR (200MHz, DMSO-d6) : 6 1.40-2. 06(4H, m), 2.96-3.48 (4H, m) , 4.62-4.73(lH/ m) , 5.01 (2H, s ) , 7.32-7.98 (14H, m) , 8 . 09 ( 1H, d, J=8.5Hz), 8 . 4 1 ( 1H, s ) , 8.54(1H, s), 8•88(1H, d, J=7.5Hz), 10.5{1H, br-s), 13 - 0 (1H, br-s). Ex amp1e 4 6-1 Methyl 31- ( { { 2 S) -5-{ [ (benzyloxy) carbonyl]amino} [ (tert-butoxycarbonyl)amino]pentanoyl)amino) - 3 -biphenylylcarboxylate -2- The target compound was obtained in a similar manner to that of Example 42-1. MS ( ( + ) ESI) m/z 598 (M+Na) Example 4 6-2 Methyl 3'-[ ( (2S)-2-amino-5-{ [ (benzyloxy) carbonyl] - amino)pentanoyl)amino]-3-biphenylylcarboxylate hydrochloride The target compound was obtained in a similar manner to that of Example 27-2. MS ((+)ESI) m/z : 476 (M+H)+. Examp1e 4 6-3 Methyl 3!-[ ( ( 2S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino] -5-{ [ (benzyloxy) carbonyl]amino)pentanoyl) -amino]-3-biphenylylcarboxylate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + )ESI) m/z : 642 (M+Na)4. Example 4 7 3'- [ ( (2S) - 2- [ (l-Benzofuran-2-ylcarbonyl)amino]-5-{[(benzyloxy)carbonyl]amino}pentanoyl)amino]- 3 -biphenylylhenylcarboxylic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 604 (M-H) ~. 2H-NMR (200MHz, DMSO-d6) : 5 1-48-1. 66(2H, m), 1.83-1.96(2H, m) , 3.07-3.09(2H, m) , 4.58-4.69(lH/ m) , 5.00(2H, s) , 7.26-8.01 (18H, m) , 8 . 19 ( 1H, s) , 8 . 82 (lHf d, J=7.5Hz), 10.3(1H, s)f 13.1(1H, br). Example 4 8-1 Methyl 31- ( { ( 2 S) - 5 -{ [ (benzyloxy) carbonyl]amino) [(tert-butoxycarbonyl)amino]pentanoyl}amino)-4- biphenylylcarboxylate -2- The target compound was obtained in a similar manner to that of Example 42-1. MS ((+)ESI) m/z : 598 (M+Na)+. Example 4 8-2 Methyl 3 ' - [ ( (2S)-2-amino-5-{ [ (benzyloxy) carbonyl] - amino}pentanoyl)amino]-4-biphenylylcarboxylate hydrochloride The target compound was obtained in a similar manner to that of Example 27-2. MS ( ( + ) ESI) m/z : 476 (M+H)+. Examp1e 4 8-3 Methyl 3 ' - [ ( ( 2 S) -2- [ (l-benzofuran-2-ylcarbonyl)-amino] - 5 - { [.(benzyloxy) carbonyl] amino}pentanoyl) -amino]-4-biphenylylcarboxylate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 642 (M+Na)+. Exampl e 4 9 3f-[ ( ( 2 S) -2- [ (l-Benzofuran-2-ylcarbonyl)amino]-5-{ [ (benzyloxy) carbonyl] aminojpentanoyl) amino] - 4 -biphenylylcarboxylic acid The target compound was obtained in a similar manner to that of Example 28. MS ((-)ESI) m/z : 604 (M-H)". 2H-NMR (200MHz, DMSO-d6) : 5 1.41-1.69(2H, m) , 1.80-1.97 (2H, m) , 3.03-3.09(2H, m), 4.58-4.69(lH, m) , 5. 01 (2H, s) , 7.29-7. 53 (10H, m) , 7.65-7.82(6H, m) , 8.02-8.06(3H/ m) , 8 . 82 ( 1H# d, J=7.5Hz) , 10. 3 ( 1H, br-s), 13. 0 ( 1H, br) . Ex ample 5 0-1 t-Butyl {2- [ ( { 2 S) -2- (tert-butoxycarbonyl) amino- 5 - { [ (benzyloxy) carbonyl] amino}pentanoyl) amino] -phenoxy}acetate The target compound was obtained in a similar manner to that of Example 42-1. MS ((+)ESI) m/z : 594 (M+Na)4. Examp1e 5 0-2 Methyl {2-[ ( (2S)-2-amino-5-{ [ (benzyloxy)carbonyl]- amino}pentanoyl)amino]phenoxy}acetate hydrochloride The target compound was obtained in a similar manner to that of Example 42-2. MS ((+)ESI) m/z : 430 (M+H)+. Examp1e 5 0-3 Methyl {2- [ ( ( 2S) -2- [ (l-benzofuran-2-ylcarbonyl)-amino]-5-{[(benzyloxy)carbonyl]amino}pentanoyl)-amino]phenoxy}acetate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 596 (M+Na)+. Examp1e 51 Sodium {2-[ ( (2 S) -2 - [ (l-benzofuran-2-ylcarbonyl)-amino]-5-{ [ (benzyloxy) carbonyl]aminojpentanoyl) -amino]phenoxy}acetate To a solution of methyl [2- [ [ ( 2 S) ~2~ [ (l-benzofuran-2-ylcarbonyl) amino] -5- [ [ (benzyloxy) carbonyl] amino]pentanoyl] amino] -phenoxy]acetate (197mg) obtained in Example 50-3 in methanol (2.OmL) and tetrahydrofuran (2.OmL), was added IN s odium hydroxide solution (0.3 4 3mL) . The mixture was stirred at room t emper a ture for 20 hours. The solvent was removed by evaporation to give the target compound (220 mg) as a white solid. MS ( (-)ESI) m/z : 558 (M-Na)". XH-NMR (200MHz, DMSO-d6) : 8 1.56-1.97(2H, m) , 3.07-3.10 (2H, m) , 4.20(2H, s ) , 4.68-4.79(lH, m) , 5.00(2H, s ) , 6.96-7.02(3H, m) , 7.33-7.80 (11H, m), 8.09-8.13(lH, m) , 8. 8 9 (1H, d, J=8.5Hz), 12.3(1H, br-s) . Ex amp 1e 5 2-1 tert-Butyl [3- ( { (2 S) - 5-{ [ (benzyloxy) carbonyl] -amino}-2-[ (tert-butoxycarbonyl) amino]pentanoyl}-amino)phenoxy]acetate The target compound was obtained in a similar manner to that of Example 42-1. MS ( ( + JESI) m/z : 594 (M+Na)+. Example 52-2 Methyl {3-[ ( (2S)-2-amino-5-{ [ (benzyloxy) carbonyl]- amino)pentanoyl)amino]phenoxy}acetate hydr o chloride The target compound was obtained in a similar manner to that of Example 42-2. MS ( ( + ) ESI) m/z : 430 (M+H)+. Examp1e 5 2-3 Methyl {3- [ ( (2S)-2-[ (l-benzofuran-2-ylcarbonyl)- amino]-5-{[(benzyloxy)carbonyl]amino}pentanoyl)-. amino]phenoxy}acetate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 594 (M+Na)+. Examp1e 5 3 Sodium {3-[((2S)-2-[(l-benzofuran-2-ylcarbonyl)-amino]-5-{[(benzyloxy)carbonyl]amino}pentanoyl)-amino]phenoxy}acetate The target compound was obtained in a similar manner to that of Example 51. MS ((-)ESI) m/z : 558 (M-Na)+. !H-NMR (200MHz, DMSO-d6) : 8 1.40-2.01(4H,m), 3.03-3.06<2H, m), 4 . 11 (2H, s ) , 4.57-4.60(lH/ m) , 5. 00 (2H, s ) , 6 . 52 ( 1H, d , J=8.0Hz), 7.06-7.51 (11H, m) , 7.67-7.80(3H, m), 9.02(1H, d, J=7.5Hz), 10.3(1H, br-s) . Examp1e 5 4-1 Methyl 3- [ 2- ( { ( 2S) - 5-{ [ (benzyloxy) carbonyl]amino}--2-[(tert-butoxycarbonyl)amino]pentanoyl}amino)-ethyl]benzoate The target compound was obtained in a similar manner to that of Example 42-1. MS ((+)ESI) m/z : 550 (M+Na)+. Examp1e 5 4-2 Methyl 3-{2-[((2S)-2-amino-5-{[(benzyloxy)- carbonyl]aminoJpentanoyl)amino]ethyl}benzoate hydrochloride The target compound was obtained in a similar manner to that of Example 27-2. MS ( ( + ) ESI) m/z : 428 (M+H)+. Examp1e 5 4-3 Methyl 3-{2 - [ ( ( 2S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino] -5-{ [ (benzyloxy) carbonyl]amino}pentanoyl) -amino]ethyl}benzoate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + )ESI) m/z : 594 (M+Na)+. Ex amp 1e 5 5 3- { 2- [ ( (2S) -2- [ (l-Benzofuran-2-ylcarbonyl) amino] - 5 -{ [ (benzyloxy) carbonyl] aminojpentanoyl) amino] - ethyl(benzoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( ( -) ESI) m/z : 556 (M-H) " . 2H-NMR (200MHz, DMSO-d6) : 5 1. 30 -1 . 52 (2H , m), 1.60-1.82(2H, m) , 2.76-2.83<2H, m), 2.95-3.01(2H, m) , 3.21-3.43{2H, m) , 4.08-4.45(lH, m) , 5.00(2H/ s ) , 7.24-7.80(15H, m) , 8 . 1 5 ( 1H, t , J=5.5Hz), 8 . 52 ( 1H, d, J=8.0Hz), 12.9(1H, br). Examp1e 5 6-1 Methyl 4 ! - ( { ( 2 S) - 5-{ [ (benzyloxy) carbonyl] amino} [ (tert-butoxycarbonyl) amino]pentanoyl}amino) - 3 - biphenylylcarboxylate -2- The target compound was obtained in a similar manner to that of Example 42-1. MS ( ( + ) ESI) m/z : 598 (M+Na)+. Examp1e 5 6-2 Methyl 4 ' - [ ( { 2 S) -2-amino-5-{ [ (benzyloxy) carbonyl] - amino}pentanoyl)amino]-3-biphenylylcarboxylate hydr ochloride The target compound was obtained in a similar manner to that of Example 27-2. MS ( ( + ) ESI) m/z 4 98 (M+Na) Examp1e 5 6-3 Methyl 4 ' - [ ( (2S)-2-[ (l-benzofuran-2-ylcarbonyl)-amino] -5-{ [ (benzyloxy) carbonyl]aminojpentanoyl)-amino]-3-biphenylylcarboxylate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 642 (M + Na) + . Examp1e 5 7 4 ! - [ ( ( 2 S) -2- [ (l-benzofuran-2-ylcarbonyl) amino] - 5 - { [ (benzyloxy) carbonyl]amino)pentanoyl) amino] -3-biphenylylcarboxylic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 604 (M-H)~. 2H-NMR (200MHz, DMSO-d6) : 8 1.48-1.69(2H, m) , 1.82-1.94 (2H, m) , 3.03-3.13(2H, m) , 4.59-4.70 (1H, m) , 5.01(2H, s ) , 7.33-7.94 (18H, m) , 8 . 18 (1H, s ) , 8.82(1H, d, J=7.5Hz), 10.3(1H, br-s), 13.1(1H, br). Example 5 8-1 Methyl 4- [2- ( { (2S)-5-amino-2-[ (1-benzofuran-2-yl- carbonyl)amino]pentanoyl}amino)ethyl]benzoate The target compound was obtained in a similar manner to that of Example 34-1. MS ( ( + ) ESI ) m/z : 438 (M + H)4. Examp1e 5 8-2 Methyl 4- [2- ( { ( 2S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino]-5-[(3-phenylpropanoyl)amino]pentanoyl}-amino)ethyl]benzoate To a solution of methyl 4-[2- [ [ (2S)-5-amino-2-[ (l-benzofuran-2-ylcarbonyl)- amino]pentanoyl]amino]ethyl]benzoate (lOOmg) obtained in Example 58-1 and 3-pheny1propanoic acid (37.8mg) inN,N-dimethylformamide (2. OmL), were added HOBT (46.3mg) and WSCD (87.6mg). The mixture was stirred at room temperature for 16 hours. The mixture was diluted with ethyl acetate ( 1OmL) , washed successively with water ( 1OmL X 2 ) and brine ( 1 OmL) , and dried over magnesium sulfate. Filtration followed by evaporation gave a crude product which was chromatographed on silica gel (Si02, 25g, eluent: hexane/ethyl acetate = 33/66 to 0/100) to give the target compound (78.2mg) as a white solid. MS ((+)ESI) m/z : 592 (M+Na)+. Examp1e 5 9 Sodium 4 - [2- ( { (2S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino]-5-[(3-phenylpropanoyl)amino]pentanoyl}-amino)ethyl]benzoate To a solution of methyl 4 - [ 2 -[ [ (2S) -2- [ (l-benzofuran-2-ylcarbonyl) amino] - 5 -[(3-phenylpropanoyl)amino]pentanoyl]amino]ethyl]-benzoate (71.8mg) obtained in Example 58-2 in methanol (l.OmL) and tetrahydrofuran (l.OmL), was added IN sodium hydroxide (0 . 13 9mL) . The mixture was refluxed for 2 hours, at which time the reaction was incomplete. Additional IN sodium hydroxide (0.025mL) was added and the mixture was refluxed for 4 hours, at which time the starting material was still remained. Additional IN sodium hydroxide (0.006mL) was added and the mixture was refluxed for 2 hours, at which time the reaction wa s comp1e t e. After cooling to room temperature, the solvent was removed by evaporation and the residual solid was washed a small amount of methanol, and dried under reduced pressure to give the target compound (23 . lmg) as a pale yellow crystalline solid. MS ( (-)ESI) m/z : 554 (M-Na)". XH-NMR (200MHz, DMSO-d6) : 5 1 . 25 -1 . 36 ( 2H, m), 1.54-1.71{2H, m), 2.32-2.40(2H, m), 2.67-2.83(4H, m) , 2.93-3.03(2H, m) , 3.18-3.42 (2H, m), 4.35-4.45 (1H, m), 7.05-7.51 (9H, m), 7.64-7.80(5H, m), 8 . 0 6 (1H, t , J=5.5Hz), 8.18(1H, t, J=5.5Hz), 8.70(1H, d, J=8.0Hz). Examp1e 6 0 Methyl 4 -{2 - [ ( ( 2S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino]- 5 -{ [ (2R)-2-hydroxy-3-phenylpropanoyl]-aminojpentanoyl)amino]ethylJbenzoate The target compound was obtained in a similar manner to that of Example 58-2. MS ((+)ESI) m/z : 608 (M+Na)+. Examp1e 61 Sodium 4 -{2 - [ ( ( 2S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino] -5-{ [ (2R)-2-hydroxy-3-phenylpropanoyl]-aminojpentanoyl)amino]ethylJbenzoate The target compound was obtained in a similar manner to that of Example 59. MS ((-)ESI) m/z : 570 (M-Na)~. ^-NMR (200MHz, DMSO-d6) : 5 1.19-1.40 (2H, m), 1.54-1.71(2H, m), 2.66-2.82(3H, m), 2.91-3.06(3H, m) , 3.17-3.46(2H, m) , 4.00-4.06(lH, m) , 4.35-4.45(lH, m) , 6.38(1H, br), 7.07-7.51 (9H, m) , 7.65-7.88(6H/ m) , 8 . 22 (1H , t , J=5.0Hz) , 8 . 59 {1H, d, J=8 . 0Hz ) . Examp1e 62 Methyl 4 -{2 - [ ( (2 S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino]-5-{ [ (2S)-2-hydroxy-3-phenylpropanoyl]-amino}pentanoyl)amino]ethyl(benzoate The target compound was obtained in a similar manner to that of Example 58-2. MS ( ( + ) ESI) m/z : 608 (M + Na) + . Examp1e 6 3 Sodium 4 -{2 - [ ( (2S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino] -5-{ [ (2S)-2-hydroxy-3-phenylpropanoyl]-amino}pentanoyl)amino]ethyl}benzoate The target compound was obtained in a similar manner to that of Example 59. MS ( (-)ESI) m/z : 570 (M-Na)~. ^-NMR (200MHz, DMSO-d6) : 8 1.23-1.42(2H, m), 1.52-1.74(2H, m) , 2. 66-2. 81 (3H, m) , 2.92-3.07 (2H, m) , 3.21-3.43(2H, m) , 4.02-4.08(lH, m), 4.35-4.46(lH, m) , 6.28 ( 1H, br), 7.08-7.50(9H, m) , 7.66-7.90(6H, m) , 8.27(1H, t, J=5.0Hz), 8.65(1H/ d, J=8.0Hz) . Ex amp 1e 6 4 Methyl 4- ( 2 - { [ ( 2 S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino] -5- ( { [ (2-chlorobenzyl) oxy] carbonyljamino) -pentanoyl]amino}ethyl)benzoate The target compound was obtained in a similar manner to that of Example 36-2. MS ( ( + )ESI) m/z : 628 (M + Na)4. Examp1e 6 5 4-(2-{ [ ( 2S) -2- [ (l-Benzofuran-2-ylcarbonyl) amino] -5- ( { [ (2-chlorobenzyl) oxy] carbonyljamino) -pentanoyl]amino}ethyl)benzoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 590 (M-H)~. ^-NMR (200MHz, DMSO-d6) : 8 1.32-1.53(2H, m) , 1.60-1.81 (2H, m) , 2.71-2.87 (2H, m) , 2.93-3.07(2H/ m), 3.21-3.44 (2H, m) , 4.34-4.45(lH, m) , 5. 08 <2H, s ) , 7.30-7.86(14H, m) , 8 . 14 { 1H, t , J=5.0Hz), 8 . 52 ( 1H , d, J = 8 . 0Hz) , 12. 8 (1H, br) . Examp1e 6 6 Methyl 4- [2- ( { { 2 S) -2- [ (l-benzofuran-2-ylcarbonyl) -amino]- 5 -[(isobutoxycarbonyl)amino]pentanoyl}-amino)ethyl]benzoate The target compound was obtained in a similar manner to that of Example 36-2. MS ( ( + ) ESI) m/z : 560 (M+Na)+. Examp1e 6 7 4- [2- ( { (2S) -2- f (l-Benzofuran-2-ylcarbonyl) amino] - 5- [ (isobutoxycarbonyl) amino]pentanoyl}amino) -ethyl]benzoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 522 (M-H)". 2H-NMR (200MHz, DMSO-d6) : 8 0. 88 ( 6H, d, J=7.0Hz), 1.28-1. 87(5H, m), 2.76-2.83(2H, m) , 2.92-3.01 (2H, m) , 3.21-3.43(2H,m), 3 . 70 (2H, d, J=7.0Hz), 4.34-4.45(lH, m) , 7 . 08 ( 1H, t , J=5.5Hz), 7.31-7.52 (4H, m ) , 7.62-7.86(5H, m) , 8.14(1H, t , J=5.5Hz), 8 . 52 ( 1H, d, J=8 . 0Hz) , 12 . 8 ( 1H, br) . Example 6 8-1 Methyl 3- [2- ( { ( 2 S) -2- [ (tert-butoxycarbonyl) amino] - 5- [ (lH-imidazol-1-ylcarbonyl) amino]pentanoyl}- amino)phenyl]propanoate To a solution of methyl 3- [ 2 -[ [ (2S) -5-amino-2- [ (tert-butoxycarbonyl) amino] pentanoyl]amino]phenyl]propanoate (6.3 6g) in tetrahydrofuran (60mL), was added ljl'-carbonyldiimidazole ( 2 . 8 8 g ) . The mixture was stirred at room temperature for 3 hours. The solvent was removed by evaporation and the residue was dissolved in ethyl acetate (6 OmL) . The solution was washed with brine (6 OmL X 1 ) and dried over magnesium sulfate- Filtration followed by evaporation gave a crude solid ( 8 . 3 3 g ) which was chromatographed on silica gel (silica gel 500g, eluent: chloroform/methanol = 100/0 to 95/5) to give the target compound (7.88g) as a pale yellow solid. Example 68-2 Methyl 3-{2 - [ ( (2S) -2- [ (tert-butoxycarbonyl) amino] -5-{[(2-pyridinylmethoxy)carbonyl]amino}pentanoyl)-amino]phenyl}propanoate To a solution of methyl 3-[2-[[(2S)-2- [ (tert-butoxycarbonyl) amino] -5-[ (lH-imidazol-1-ylcarbonyl)amino]pentanoyl]amino]phenyl]propanoate (500mg) obtained in Example 68-1 in acetonitrile (5. 0mL)f was added 2-pyridinemethanol {0.19 8mL) . The mixture was refluxed for 17 hours. After cooling to room temperature, the solvent was removed by evaporation and the residue was chromatographed on silica gel (eluent: chloroform/methanol = 100/0 to 95/5) to give the target compound (226mg) as a light br own solid. Examp1e 6 8-3 Methyl 3-{2- [ ( (2S) -2- [ (l-benzothien-2-ylcarbonyl) -amino] - 5 -{ [ (2-pyridinylmethoxy) carbonyl] amino}-pentanoyl)amino]phenyl}propanoate To a solution of methyl 3- [2- [ [ (2S) -2- [ (tert-butoxycarbonyl) amino] -5- [ [ (2-pyridinylmethoxy)carbonyl]amino]pentanoyl]amino]-pheny1]propanoate (226mg) obtained in Example 68-2 in ethyl acetate (lmL), were added 4N hydrogen chloride in ethyl acetate (6mL) andmethanol ( lmL ) .. The mixture was stirred at room temperature for 20 minutes. The solvent was removed by evaporation and the residue was dissolved in N,N-dimethylformamide (4mL). To the solution, were added l-benzothiophene-2-carboxylic acid (83.8mg), 1-hydroxybenzotriazole ( 8 6.7mg) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (0.195mL). The mixture was stirred at room temperature for 3 hours. The mixture was diluted with ethyl acetate (l0mL) , washed with water (lOmL), saturated aqueous sodium hydrogencarbonate (lOmL), water ( 10 mL) , and brine (lOmL), and dried over magnesium sulfate. Filtration followed by evaporation gave a solid which was suspended in chloroform (lmL) and ethyl acetate (lmL) . After stirring for 1 hour, the precipitates were collected by filtration, washed with ethyl acetate and dried under reduced pressure to give the target compound (12 3mg) as a pale orange solid. MS ((+)ESI) m/z : 611 (M + Na) + . Example 6 9 Sodium 3-{2- [ ( ( 2S) -2- [ (l-benzothien-2-ylcarbonyl) -amino] - 5 - { [ (2-pyridinylmethoxy)carbonyl]amino}-pentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 59. MS ( (-)ESI) m/z : 573 ( M-N a) *. !H-NMR (200MHz, DMSO-d6) : 5 1.48-1.73(2H, m) 1.82-2.09<2H, m) , 2.21-2. 37(2Hf m) , 2.63-2.91(2H, m) 3.03-3.23(2H, m), 4.60-4.72(lH/ m), 5.06 ( 2H, s) 6.95-7.49(8H, m) , 7.74-8.04(5H, m) , 8.51(1H, d J=4.5Hz), 8.62(1H, s), 9.29(1H, d, J=8.0Hz), 12.5(1H br) . Examp1e 7 0-1 Methyl 3- { 2- [ ( ( 2S) -2- [ (tert-butoxycarbonyl) amino] -5 -{ [ (3-thienylmethoxyfcarbonyl]amino}pentanoyl)-amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 68-2. Example 7 0-2 Methyl 3-{2- [ ( ( 2S) -2- [ (l-benzothien-2-ylcarbonyl) -amino] -5-{ [ (3-thienylmethoxy)carbonyl]amino}-pentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 68-3. MS ( ( + ) ESI) m/z : 616 (M + Na) + . Ex amp 1e 7 1 3- { 2 - [ ( ( 2S) -2- [ (l-Benzothien-2-ylcarbonyl) amino] -5- { [ (3-thienylmethoxy) carbonyl]aminojpentanoyl) -amino]phenylJpropanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 578 (M-H)~. ^-NMR (200MHz, DMSO-d6) : 5 1.46-2.06(4H, m) , 2.43-2.57 (2H, m) , 2.79-2.86(2H, m) , 3.03-3.13(2H, m) , 4.58-4.69(lH, m) , 4 . 99 (2H, s) , 7.07-7.52 (10H, m) , 7.90-8.08(2H, m) , 8 .2 9 ( 1H, s ) , 7 . 7 3 ( 1H, d, J = 7.5Hz) , 9.60(1H, s ) , 12 . 2 ( 1H, br). Example 72-1 Methyl 3-{2- [ ( (2S) -2- [ (tert-butoxycarbonyl)amino] -5 -{ [ (2-naphthylmethoxy) carbonyl] aminojpentanoyl) -amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 68-2. Example 72-2 Methyl 3 - {2 - [ ( ( 2 S) -2- [ (l-benzothien-2-ylcarbonyl) -amino] - 5 -{ [ (2-naphthylmethoxy) carbonyl] amino}-pentanoyl)amino]phenylJpropanoate The target compound was obtained in a similar manner to that of Example 68-3. MS ( ( + ) ESI) m/z 660 (M+Na) Examp1e 7 3 3-{2- [ ( (2S) -2- [ (l-Benzothien-2-ylcarbonyl) amino] -5 -{ [ (2-naphthylmethoxy) carbonyl] aminojpentanoyl) -amino]phenylJpropanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 622 (M-H)~. !H-NMR (200MHz, DMSO-d6) : 8 1.44-2.05(4H, m), 2.47-2.54 (2H, m), 2.75-2.86(2H, m) , 3.04-3.16(2H, m) , 4.61-4.71 (1H, m), 5. 19 (2H, s ) , 7.00-7.54 (10H, m) , 7 . 82 -8 . 05 ( 6H, m), 8.30(1H, s), 8.95(1H, d , J = 7.5Hz) , 9. 61 (1H, s) , 12. 2 ( 1H, br) . Example 7 4-1 Methyl 3-(2-{ [ ( 2S) -2- [ (tert-butoxycarbonyl) amino]-5-({[(2-methylbenzyl)oxy]carbonyl}amino)-pentanoyl]amino}phenyl)propanoate The target compound was obtained in a similar manner to that of Example 68-2. Example 7 4-2 Methyl 3- (2 -{ [ (2S) -2- [ (l-benzothien-2-ylcarbonyl) -amino]-5-({[(2-methylbenzyl)oxy]carbonyl}amino)-pentanoyl]amino}phenyl)propanoate The target compound was obtained in a similar manner to that of Example 68-3. MS {(+)ESI) m/z : 624 (M+Na)+. Ex amp 1e 7 5 3-(2-{[(2S)-2-[(l-Benzothien-2-ylcarbonyl)amino]-5-({[(2-methylbenzyl)oxy]carbonyl}amino)-pentanoyl]amino}phenyl)propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 586 (M-H)~. XH-NMR (200MHz, DMSO-d6) : 8 1.46-2.02 (4H,m), 2.27 ( 3H, s) , 2.46-2.54 (2H, m) , 2.74-2.86(2H, m) , 3.04-3.14 (2H, m) , 4.60-4.70(lH, m) , 5. 02 (2H, s ) , 7.10-7.51 (11H, m) , 7.94-8.05(2H, m) , 8 . 30 ( 1H, s ) , 8 . 94 ( 1H, d, J=7.5Hz), 9.60(1H, s) , 12 . 2 ( 1H, br) . Example 7 6-1 Methyl 3- ( 2 - { [ ( 2S) -2- [ (tert-butoxycarbonyl)amino] -5- ( { [ (3-methylbenzyl) oxy] carbonyl}araino) -pentanoyl]aminojphenyl)propanoate The target compound was obtained in a similar manner to that of Example 68-2. Example 7 6-2 Methyl 3- (2- { [ ( 2S) -2- [ (l-benzothien-2-ylcarbonyl) -amino] -5- ({ [ (3-methylbenzyl) oxy] carbonyl}amino)-pentanoyl]aminojphenyl)propanoate The target compound was obtained in a similar manner to that of Example 68-3. MS ((+)ESI) m/z : 624 (M+Na)+. Ex ample 7 7 3- (2- { [ (2S ) -2- [ (l-Benzothien-2-ylcarbonyl) amino] -5-({[(3-methylbenzyl)oxy]carbonyl}amino)-pentanoyl]amino}phenyl)propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 586 (M-H)". !H-NMR (200MHzf DMSO-d6) : 8 1 . 47-2 . 00 (4H, m) , 2.28 (3H, s), 2.46-2.54(2H, m) , 2.78-2.86(2H/ m) , 3.05-3.14 (2H, m) , 4.60-4.70 (1H, m) , 4 . 97 (2H, s ) , 7.14-7.48 (11H, m) , 7 . 94-8 . 05 (2H, m), B.30(1H, s), 8.94(1H/ d, J = 7.5Hz), 9. 61 (1H, s) , 12.2 ( 1H, br) . Example 7 8 Methyl 3- [2- ( { (2S) -5- ( { [ (2-chlorobenzyl) oxy] -carbonyl}amino)-2-[(2-quinolinylcarbonyl)amino]-pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 639 (M+Na)*. Examp1e 7 9 3- [2- ( { (2S)-5-({ [ (2-Chlorobenzyl)oxy]carbonyl}-amino)-2-[(2-quinolinylcarbonyl)amino]pentanoyl}-amino)phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 601 (M-H)~. !H-NMR (200MHz, DMSO-d6) : 8 1.52-1. 67(2H, m), 1.86-2.07(2H, m), 2.45-2.54(2H, m) , 2.79-2.87 (2H, m) , 3.05-3.14 (2H, m) , 4.80-4.90(lH, m), 5. 06 (2H, s) , 7.15-7.57 (9H, m) , 7.70-7.93(2H, m) , 8.09-8.22 (3H, m) , 8 . 61 ( 1H , d, J=8 . 5Hz) , 8 . 91 ( 1H, d, J==8 . 5Hz ) , 9. 75 ( 1H, br-s) , 12 . 2 ( 1H, br-s). Ex amp1e 8 0 Benzyl { (4S)-4-[ (l-benzofuran-2-ylcarbonyl)amino]- 5 - [ (5-cyanopentyl)amino]-5-oxopentyl}carbamate The target compound was obtained in a similar manner to that of Example 42-1. Examp1e 8 1 Benzyl ( ( 4S) -4- [ (l-benzofuran-2-ylcarbonyl) amino] -5-oxo-5-{[5-(2H-tetrazol-5-yl)pentyl]amino}-pentyl) carbamate To a solution of benzyl [ { 4 S) - 4 - [ (l-benzofuran-2-ylcarbonyl)amino]-5-[ (5-cyanopentyl)amino]-5-oxopentyl]carbamate (300mg) obtained in Example 80 in l-methyl-2-pyrrolidinone (6mL), were added sodium azide ( 19 3mg) and triethylamine hydrochloride (193mg) . The mixture was stirred at 14 0*C for 20 hours. After cooling to room temperature, the mixture was quenched by the addition of IN hydrochloric acid (20mL) and extracted with ethyl acetate (2 0mL X l , 10mL X 1) . The extracts were combined and washed with water (20mLX2) and brine ( 2 0mL X l ) , and dried over magnesium sulfate. Filtration followed by evaporation gave a crude product (280mg) which was chromatographed on silica gel (eluent: chloroform/methanol = 99/1 to 95/5) to give the target compound ( 155mg) as a yellow solid. MS ( ( + ) E SI) m/z : 570 ( M + N a ) + . aH-NMR (200MHz, DMSO-d6) : 8 1.23-1.84 (10H, m) , 2.83-3.13(6H, m) , 4.38-4.49(lH, m) , 5.01<2H, s) , 7.26-7.52<8H, m) , 7. 64-7.81 (3H, m) , 8 . 06 ( 1H, t , J=5.5Hz)/ 8 . 52 ( 1H, d, J=8.0Hz). Example 82-1 Ethyl 4-|2-[ ( (2S)-2-amino-5-( [ (benzyloxy)- carbonyl]amino}pentanoyl)amino]phenyl}butanoate hydr o ch1 or i de To a solution of ethyl 4-[2-[[(2S)-5-[ [ (benzyloxy) carbonyl] amino] -2- [ (tert-butoxy-carbonyl)amino]pentanoyl]amino]phenyl] butanoate ( 518mg) in 1,4-dioxane ( ImL) , was added 4N hydrogen chloride in 1,4-dioxane (4mL)• The mixture was stirred at room temperature for 2 hours. The solvent was removed by evaporation to give the target compound (476mg) as a pale yellow solid-Example 82-2 Ethyl 4 -{2 - [ ( ( 2 S) -5-{ [ (benzyloxy) carbonyl]amino}-2 -{ [ (l-methyl-lH-indol-2-yl)carbonyl]amino}-pentanoyl)amino]phenyl}butanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z 63 5 (M+Na) Ex amp 1e 8 3 4 - { 2 - [ ( (2S)-5-{ [ (Benzyloxy)carbonyl]amino}~2-{ [ ( 1- methyl-lH-indol-2-yl)carbonyl]aminojpentanoyl)- amino]phenyl}butanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( ( -) ESI ) m/z : 583 (M-H) " . 2H-NMR (200MHz, DMSO-d6) : 6 1.53-1.95(6H, m) , 2.18-2.26(2H, m) , 2.55-2.63(2H, m) , 3.05-3.14 (2H, m) , 3. 99 < 3H, s ) , 4.57-4.68(lH, m), 5.02(2H, s) , 7 . 07-7 . 4 0 ( 13H, m), 7.53(1H, d, J=8.0Hz), 7.66(lHf df J=8.0Hz) , 8 . 61 (1H, d, J = 7.5Hz), 9 . 44 ( 1H, br-s), 12 . 1 ( 1H, br) . Examp1e 8 4 Ethyl 4- [2- ( { (2S)-5-{ [ (benzyloxy) carbonyl] amino}-2- [ (2-quinolinylcarbonyl) amino]pentanoyl}amino) -phenyl]butanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 633 (M+Na)+. Examp1e 8 5 4-[2- ({ (2S)-5-{ [ (Benzyloxy)carbonyl]amino}-2-[ (2-quinolinylcarbonyl) amino]pentanoyl}amino)phenyl] -butanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 581 (M-H)". ^-NMR (200MHz, DMSO-d6) : 8 1.51-1.78 (4H, m) , 1.88-2.03(2H/ m) , 2.17-2.24 (2H, m) , 2.55-2.62 (2H, m) , 4.80-4.90 (1H, m) , 4 . 99 (2H, s ) , 7.15-7.42 (10H, m) , 7.70-7.78 (1H, m) , 7.85-7.93(lH, m) , 8.09-8.22(2H, m), 8 . 61 ( 1H, d, J=8.0Hz), 8 . 92 (1H, d, J=8.0Hz), 9 . 65 (1H, br-s ) , 12 . 1 (1H, br) . Ex amp 1e 8 6-1 Methyl 3- (2- { [ (2S ) -2- [ (tert-butoxycarbonyl) amino] -5-({ t (4-methylbenzyl)oxy]carbonyljamino)-pentanoyl]amino}phenyl)propanoate In a reaction vessel, was added a solution of methyl 3- [2- [ [ (2S) -2- [ (tert-butoxycarbonyl) amino] - 5-[ (lH-imidazol-1-ylcarbonyl) amino]pentanoyl]amino] -phenyl]propanoate (500mg) and (4-methylphenyl)- methanol (251mg) in acetonitrile (5mL). The vessel was placed in a microwave. The irradiation was adjusted to keep the temperature 140ºC and the reaction was performed for 2 hours. After cooling to room temperature, the solvent was removed by evaporation, and the residue was chromatographed on silica gel (eluent: hexane/ethyl acetate = 2/1 to 1/1) to give the target compound (376mg) as a white solid. MS ( ( + ) ESI ) m/z : 564 (M+Na)+. Example 8 6-2 Methyl 3- (2-{ [ (2S)-2-amino-5-({ [ (4-methylbenzyl)-oxy]carbonyl}amino)pentanoyl]amino}phenyl)-propanoate hydrochloride The target compound was obtained in a similar manner to that of Example 82-1. Examp1e 8 6-3 Methyl 3-{2-[ ( (2S) -5- ( { [ (4-methylbenzyl) oxy] -carbonyl}amino)-2-{[(l-methyl-lH-indol-2-yl)-carbonyl]aminojpentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 621 (M + Na)+. Examp1e 8 7 3-{2-[ ( (2S) -5- ({ [ (4-Methylbenzyl)oxy]carbonyl}-amino)-2-{ [ (l-methyl-lH-indol-2-yl)carbonyl]-amino}pentanoyl)amino]phenyl}propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-) ESI) m/z : 583 (M-H) '. 1H-NMR (200MHz, DMSO-d6) : 8 1.52-1.69(2H, m) , 1.81-1.95(2H, m), 2.27(3H, s) , 2.47-2.54 (2H, m) , 2.79-2.86(2H, m) , 3.03-3.13(2H, m) , 3. 98 ( 3H, s ) , 4.55-4. 66 { 1H, m), 4 . 96 (2H, s ) , 7.07-7.37(12H, m) , 7.53(1H, d, J = 8.0Hz)/ 7.65(1H, d, J = 7.5Hz) , 8.62(1H, d, J = 7. 5Hz) , 9.56(1H, br-s), 12.1<1H, br). Examp1e 8 8 Methyl 3- [2- ( { (2S)-5-({ [ (4-rnethylbenzyl) oxy] -carbonyl}amino) -2- [ (2-quinolinylcarbonyl) amino] -pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS {(+)ESI) m/z : 619 (M+Na)+. Example 89 3- t 2 - ({ (2S) -5- ({ [(4-Methylbenzyl)oxy]carbonyl}-amino)-2-[(2-quinolinylcarbonyl)amino]pentanoyl}-amino)phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 581 (M-H)'. 2H-NMR (200MHz, DMSO-d6) : 5 1.56-1.66(2H, m), 1.85-2.06{2H, m) , 2.25(3H, s) , 2.45~2.51(2H, m) , 2.80-2.87 (2H, m) , 3.04-3.13(2H, m) , 4.81-4.87 (1H, m) , 4 . 94 (2H , s ) , 7.10-7.40(9H, m ) , 7.71-7.93 (2H, m) , 8.09-8.23 (3H, m) , 8.61(1H, d, J=8.5Hz), 8.92(1H, d, J=8.5Hz), 9 . 76 (1H, br-s), 12.2(1H, br). Example 9 0-1 Methyl 3-{2 - [ ( (2S) -2- [ (tert-butoxycarbonyl)amino]-5-{ [ (3-furylmethoxy)carbonyl]amino}pentanoyl)-amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 86-1. MS ( ( + ) ESI) m/z 54 0 (M + Na) Example 90-2 Methyl 3- { 2- [ ( (2S)-2-amino-5-{ [ (3-furylmethoxy) -carbonyl]aminojpentanoyl)amino]phenyl}propanoate hydro chlo r i de The target compound was obtained in a similar manner to that of Example 82-1. Example 90-3 Methyl 3 - { 2 - [ ( (2S) -5-{ [ (3-furylmethoxy) carbonyl] - amino}-2-{ [ (l-methyl-lH-indol-2-yl) carbonyl] - amino}pentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + )ESI) m/z : 597 (M + Na) + . Ex amp1e 91 3-{2- [ ( ( 2S) -5-{ [ (3-Furylmethoxy) carbonyl]amino}-2-{[(l-methyl-lH-indol-2-yl)carbonyl]amino}-penta'noyl) amino]phenyl}propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 559 (M-H) ". ^-NMR (200MHz, DMS0-d6) : 8 1.51-1. 69(2H, m) , 1.81-1.94(2H, m) , 2.46-2.54 (2H, m) , 2.79-2.86(2H, m) , 3.03-3.12{2H, m) , 3.98(3H, s ) , 4.55-4.65(lH, m) , 4.86(2H/ s) , 6 . 4 8 (1H, d, J = 1.5Hz), 7.07-7.37 (8H, m) , 7.51-7.68(4H,m), 8.62(1H, d, J=7.5Hz), 9 . 55 ( 1H, br-s), 12.1(1H, br). Example 92 Methyl 3- [ 2- ( { (2S) -5-{ [ (3-furylmethoxy) carbonyl] -amino}-2- [ (2-quinolinylcarbonyl) amino]pentanoyl}-amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 595 (M + Na) + . Ex amp 1e 9 3 3-[2-({(2S)-5-{[(3-Furylmethoxy)carbonyl]amino}-2-[(2-quinolinylcarbonyl)amino]pentanoyl}amino)-phenyljpropanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 557 (M-H)". ^-NMR (200MHz, DMSO-d6) : 5 1.51-1.65(2H, m), 1.85-2.06(2H, m), 2.45-2.53(2H, m), 2.79-2.87(2H, m), 3.03-3.11 (2H, m) , 4.79-4.90(3H, m), 6.46(1H, s), 7.11-7.39(5H, m), 7.59-7.90(4H, m) , 8.09-8.22(3H, m), 8.61(1H, d, J=8 . 5Hz) , 8.91(1H, d, J=8.0Hz), 9.75(1H, br-s), 12.1(1H, br). Ex amp 1e 9 4-1 Methyl 3- { 2 - [ ( (2S) -2- [ (tert-butoxycarbonyl) amino] -5 - { [ (3-pyridinylmethoxy) carbonyl] aminojpentanoyl) -amino]phenylJpropanoate The target compound was obtained in a similar manner to that of Example 86-1. MS ( ( + ) ESI) m/z : 551 (M + Na)+. Example 94-2 Methyl 3-{2-[((2S)-2-amino-5-{[(3-pyridinyl- methoxy)carbonyl]aminojpentanoyl)amino]phenyl}-propanoate dihydrochloride The target compound was obtained in a similar manner to that of Example 82-1. Example 9 4-3 Methyl 3-{2-[ ( (2S) -2-{ [ (l-methyl-lH-indol-2-yl)-carbonyl]amino}-5-{ [ (3-pyridinylmethoxy) carbonyl] -amino}pentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 608 (M+Na)+. Examp1e 9 5 Sodium 3-{2-[ ( (2S)-2-{ [ (l-methyl-lH-indol-2-yl)-carbonyl]amino}-5-{[(3-pyridinylmethoxy)carbonyl]-aminojpentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 59. MS {(-)ESI) m/z : 570 (M-Na)~. XH-NMR (200MHz, DMS0-d6) : 8 1.50-1.68(2H, m) , 1.81-2.04 (2H, m) , 2.25-2.30(2H/ m) , 2.73-2.78 (2H, m) , 3.07-3.16{2H, m) , 3.99(3H, s ) , 4.61-4.72(lHf m), 5. 04 (2H, s ) , 6.97-7.15<4H, m) , 7.23-7.65(6H, m) , 7.75-7.85{3H,m), 8.50(1H, dd, J=l . 5 , 4 . 5Hz) , 8 . 57 ( 1H, d, J=2.0Hz) , 8 . 74 ( 1H, d, J=8.5Hz). Examp1e 9 6 Methyl 3-[2-({(2S)-5-{[(3-pyridinylmethoxy)- carbonyl]amino}~2-[(2-quinolinylcarbonyl)amino]-pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar * manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 606 (M + Na) + . Ex amp 1e 9 7 Sodium 3-[2-({(2S)-5-{[ (3-pyridinylmethoxy) -carbonyl]amino}-2-[(2-quinolinylcarbonyl)amino]-pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 59. MS ( (-)ESI) m/z : 568 (M-Na)". 2H-NMR (200MHz, DMSO-d6) : 5 1.46-1.68 (2H, m) , 1.85-2.13(2H, m) , 2.28-2.31 (2H, m), 2.64-2.86(2H, m) , 3.10-3.18 (2H, m) , 4.82-4.92(lH, m) , 5.03(2H, s ) , 6.97-7.18 (3H, m) , 7.33-7. 39 (1H r m), 7.70-7.94 (5H, m) , 8.1K1H; d, J = 8.0Hz), 8.21 ( 1H, d, J=8. 5Hz) , 8.48-8.63(3H/ m), 9. 00 ( 1H, d, J=8.5Hz), 13 . 0 ( 1H, br - s ) . Example 9 8-1 Methyl 3- { 2- [ ( (2S) -2- [ (tert-butoxycarbonyl) amino] -5 - {[(4-pyridinylmethoxy)carbonyl]amino}pentanoyl)-amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 86-1. MS ((+)ESI) m/z : 551 (M+Na)+. Example 98-2 Methyl 3-{2- [( (2S) -2-amino-5-([ (4-pyridinylmethoxy) carbonyl]amino}pentanoyl)amino]phenyl}-propanoate dihydrochloride The target compound was obtained in a similar manner to that of Example 82-1. Example 98-3 Methyl 3-[2-({(2S)-5-{[ (4-pyridinylmethoxy) - carbonyl]amino}-2-[(2-quinolinylcarbonyl)amino]- pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 606 (M+Na)'. Example 99 Sodium 3- [ 2- ( { {2S) - 5-{ [ (4-pyridinylmethoxy)- carbonyl]amino}-2-[ (2-quinolinylcarbonyl) amino] -pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 59. MS ((-)ESI) m/z : 568 (M-Na)~. ^-NMR (200MHz, DMSO-d6) : 8 1.45-1.73 (2H, m), 1.86-2.18 (2H, m) , 2.26-2.36(2H, m) , 2.70-2.84 (2H, m) , 3.12-3.21<2H, m), 4.84-4.95(lH/ m) , 5. 04 (2H, s) , 7.01-7.18(3H,m), 7 . 31 (2H, d, J=5.5Hz), 7.70-8.13(5H, m), 8,22(2H/ d, J=8.5Hz) , 8 . 51 (2H, d, J=6.0Hz) , 8 . 61 ( 1H, d, J= 8.5Hz), 9.01(1H, d, J = 8.5Hz), 13. 0 ( 1H, br-s ) . Example 10 0-1 Methyl 3-(2-{[(2S)-2-[(tert-butoxycarbonyl)-amino] -5- ( { [ (3-chlorobenzyl) oxy] carbonyl}amino) -pentanoyl]amino}phenyl)propanoate The target compound was obtained in a similar manner to that of Example 86-1. MS ((+)ESI) m/z : 584 (M+Na)1. Example 10 0-2 Methyl 3- ( 2- { [ (2S)-2-amino-5-({ [ (3-chlorobenzyl) -oxy]carbonyl}amino)pentanoyl]amino}phenyl)-propanoate hydrochloride The target compound was obtained in a similar manner to that of Example 82-1. Example 100-3 Methyl 3-{2- [ ( (2S) -5- ( { [ (3-chlorobenzyl)oxy] -carbonyl}amino)-2-{[(l-methyl-lH-indol-2-yl)-carbonyl]aminojpentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ({+)ESI) m/z : 641 (M+Na)+. Examp1e 10 1 3-{2-[((2S)-5-({[(3-Chlorobenzyl)oxy]carbonyl}-amino) -2 -{ [ (l-methyl-lH-indol-2-yl) carbonyl] -aminojpentanoyl)amino]phenyl}propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 603 (M-H) ~• aH-NMR (200MHz, DMSO-d6) : 8 1.50-1.70 (2H, m) , 1.83-1.96(2H, m) , 2.47-2. 55(2H, m) , 2.79-2.87 (2H, m) , 3.05-3.14 (2H, m) , 4 . 01 ( 3H, s) , 4.56-4. 66 ( 1H, m) , 5.02(2H, s ) , 7.07-7.41 (12H, m) , 7.53(1H, d, J=8.0Hz) , 7.65(1H, d, J=8.0Hz), 8.63(1H, d, J=8.0Hz)/ 9.55(1H, br-s) , 12. 1 ( 1H, br) . Example 102 Methyl 3- [2- ( { (2S) -5- ( { [ (3-chlorobenzyl) oxy] -carbonyl}amino)-2-[(2-quinolinylcarbonyl)amino]-pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + )ESI) m/z : 639 (M+Na)+. Ex ample 10 3 3-[2-({(2S)-5-({[(3-Chlorobenzyl)oxy]carbonyl}-amino) -2- [ (2-quinolinylcarbonyl)amino]pentanoyl } -amino)phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 601 (M-H) ". aH-NMR (200MHz, DMSO-d6) : 5 1.53-1.68(2H, m), 1.87-2.08(2H, m) , 2.46-2.55(211, m), 2.81-2.88 (2H, m) , 3.05-3.14(2H, m) , 4.82-4.92 (1H, m) , 5. 00 (2H, s) , 7.13-7.38(9H, m) , 7.74(1H/ t , J = 7 . 0Hz) , 7.89(1H, t , J=7.0Hz), 8. 09-8.22 (3H, m) , 8 . 61 ( 1H, d, J=8.5Hz), 8.92(1H, d, J=8.0Hz), 9.76(1H, br-s), 12.2(1H, br) . Example 10 4-1 Methyl 3-(2-{ [ (2S)-2-[ (tert-butoxycarbonyl)-amino]-5-({[(4-chlorobenzyl)oxy]carbonyl}amino)-pentanoyl]amino}phenyl)propanoate The target compound was obtained in a similar manner to that of Example 86-1. MS ( ( + ) ESI) m/z : 584 (M + Na) + . Example 10 4-2 Methyl 3-(2-{ [(2S)-2-amino-5-({ [ (4-chlorobenzyl) -oxy]carbonyl}amino)pentanoyl]amino}phenyl) -propanoate hydrochloride The target compound was obtained in a similar manner to that of Example 82-1. Example 10 4-3 Methyl 3-{2- [ ( (2S) -5- ( { [ (4-chlorobenzyl) oxy] -carbonyl}amino)-2-{[(l-methyl-lH-indol-2-yl)-carbonyl]amino}pentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 641 (M+Na)+. Example 10 5 3-{2- [ ( (2S) -5- ( { [ (4-Chlorobenzyl)oxy]carbonyl}-amino)-2-{[(l-methyl-lH-indol-2-yl)carbonyl]-amino}pentanoyl)amino]phenyl}propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 603 (M-H)~. aH-NMR (200MHz, DMSO-d6) : 8 1 . 53 - 1 . 70 (2H , m), 1.82-1.96(2H, m) , 2.47-2.55(2H, m) , 2.79-2.87 (2H, m) , 3.04-3.14 (2H, m) , 3.98(3H, s ) , 4.56-4.67 (1H, m), 5 . 01 (2H, s), 7.07-7.44(12H, m), 7 . 53 (1H, d7 J=8.5Hz), 7.66(1H, d, J=7.5Hz), 8.62(1H, d, J=7.5Hz), 9.55(1H, br-s), 12 . 1 ( 1H, br). Examp1e 10 6 Methyl 3-[2-({(2S)-5-({[(4-chlorobenzyl)oxy]-carbonyljamino) -2- [ (2-quinolinylcarbonyl) amino] -pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ( { + ) E SI) m/z : 639 ( M + N a) + . Ex amp 1e 10 7 3-[2-({ (2S) -5- ( { [ (4-Chlorobenzyl)oxy]carbonyl}-amino)-2-[(2-quinolinylcarbonyl)amino]pentanoyl}-amino)phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-) ESI) m/z : 601 (M-H) ". aH-NMR (200MHz, DMSO-d6) : 8 1.52-1.67(2H/ m) 1.86-2.07(2H, m) , 2.46-2.54 (2H, m) , 2.80-2.88 (2H, m) 3.04-3.14 (2H, m) , 4.81-4.91 (1H, m), 4 . 99 (2H, s) 7.16-7.40OH, m) , 7.70-7.93(2H, m) , 8. 09-8.23 (3H, m) 8.61 (1H, d, J = 8.5Hz), B.92(1H/ d , J=8.0Hz), 9 . 75 (1H br-s) , 12.2 ( 1H, br). Example 10 8-1 Methyl 3-(2-( [ (2S)-2-[ (tert-butoxycarbonyl) -amino] -5- ( { [ (2-methylbenzyl) oxy] carbonyl}amino) -pentanoyl]amino}phenyl)propanoate The target compound was obtained in a similar manner to that of Example 86-1. Example 10 8-2 Methyl 3- (2-{ [ (2S)-2-amino-5-({ [ (2-methylbenzyl) -oxy] carbonyl}amino)pentanoyl]amino}phenyl) -propanoate hydrochloride The target compound was obtained in a similar manner to that of Example 82-1. Example 10 8-3 Methyl 3-{2-[((2S)-5-(([(2-methylbenzyl)oxy]-carbonyl}amino)-2-{ [ (l-methyl-lH-indol-2-yl)-carbonyl]amino}pentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 621 (M+Na)+. Example 109 3- { 2- [ ( (2S) -5- ({ [ (2-Methylbenzyl)oxy]carbonyl}~ amino)-2-{ [ (l-methyl-lH-indol-2-yl) carbonyl] -aminojpentanoyl) ami no]phenyl}propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 583 (M-H)". 2H-NMR (200MHz, DMSO-d6) : d 1.52-1.69(2H, m) , 1.81-1.95(2H, m), 2 .27 (3H, s ) , 2.46-2.54(2H, m) , 2.79-2.86(2H, m) , 3.04-3.13(2H, m) , 3. 98 ( 3H, s ) , 4.55-4. 66 ( 1H, m) , 5 . 01 (2H, s) , 7.07-7.36(12H, m) , 7 . 53 ( 1H, d, J = 8 . 0Hz) , 7 . 65 ( 1H, d, J= 8.0Hz), 8.62(1H, d, J = 7.5Hz), 9.56(1H, br-s), 12.1(1H, br) . Examp1e 110 Methyl 3- [2- ( { (2S) -5- ( { [ (2-methylbenzyl) oxy] -carbonyl}amino) -2- [ (2-quinolinylcarbonyl) amino] -pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 619 (M+Na)+. Examp1e 111 3-[2-({(2S)-5-({[(2-Methylbenzyl)oxy]carbonyl}~ amino) -2- [ (2-quinolinylcarbonyl) amino]pentanoyl}-amino)phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 581 (M-H)~. ^-NMR (200MHz, DMSO-d6) : 8 1.51-1.66(2H, m) , 1.86-2.07 (2H, m) , 2 .25 (3H, s) , 2.45-2.53(2H, m) , 2.80-2.87(2H, m) , 3.04-3.13(2H, m) , 4.80-4.91 (1H, m) , 4 . 99 (2H, s ) , 7.12-7.40OH, m) , 7.70-7.93 (2H, m) , 8.09-8.22 (3H, m) , 8.61(1H, d, J=8.5Hz), 8.91(1H, d, J = 8.5Hz), 9. 7 6 (1H, br-s) , 12 .2 (1H, br). Example 112-1 Methyl 3-(2-{[(2S)-2-[(tert-butoxycarbonyl)- amino] -5- ( { [ (3-methylbenzyl) oxy] carbonyl}amino) -pentanoyl]amino}phenyl)propanoate The target compound was obtained in a similar manner to that of Example 86-1. Example 112-2 Methyl 3- (2-{ [ (2S) -2~amino-5- ({ [ (3-methylbenzyl) -oxy]carbonyl}amino)pentanoyl]amino}phenyl)-propanoate hydrochloride The target compound was obtained in a similar manner to that of Example 82-1. Examp1e 11 2 - 3 Methyl 3-{2- [ ( (2S) -5- ({ [ (3-methylbenzyl) oxy] -carbonyl}amino) -2 -{ [ (l-methyl-lH-indol-2-yl) -carbonyl]amino}pentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z 621 (M+Na)+. Examp1e 113 3- {2- [ ( (2S) -5- ({ [ (3-Methylbenzyl)oxy]carbonyl}-amino)-2-{[(l-methyl-lH-indol-2-yl)carbonyl]-aminojpentanoyl)amino]phenyl(propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 583 (M-H) ~ . aH-NMR (200MHz, DMSO-d6) ; 5 1.53-1.70{2H, m) , 1.82-1.96(2H, m) , 2.28 ( 3H, s) , 2.47-2.54 (2H, m), 2.79-2.87 (2H, m) , 3.05-3.14(2H, m) , 3 .98 ( 3H, s ) , 4.56-4.66(lH, m) , 4 . 97 ( 2H, s ) , 7.07-7.36(12H, m) , 7 . 53 ( 1H, d, J=8.5Hz), 7 . 65 ( 1H, d, J=8.5Hz) , 8.63(1H, d, J = 7.5Hz) , 9. 56 ( 1H, br-s), 12 . 2 ( 1H, br) . Example 114 Methyl 3- [ 2- ( { (2S)-5-({ [ ( 3-methylbenzyl)oxy] -carbonyl}amino) -2- [ (2-quinolinylcarbonyl) amino] -pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 619 (M + Na) + . Examp1e 115 3-[2-({(2S)-5-({[(3-Methylbenzyl)oxy]carbonyl}-amino) -2- [ (2-quinolinylcarbonyl) amino]pentanoyl } -amino)phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( ( -)ESI) m/z : 581 (M-H)". ^-NMR (200MHz, DMSO-d6) : 5 1.54-1.67<2H, m) , 1.90-2.04 (2H, m) , 2. 27 (3H, s), 2.46-2.54 (2H, m) , 2.81-2.88 (2H, m) , 3.05-3.14(2H, m) , 4.81-4.92 (1H, m) , 4. 95 (2H, s ) , 7.12-7.39<9H, m) , 7.71-7.93(2H, m) , 8.09-8.23(3H, m) , 8.61(1H, d, J=8 . 5Hz) , 8 . 92 ( 1H, d, J=8. 0Hz) , 9.76 (1H, br-s) , 12.2(lHf br). Example 116-1 Methyl 3-[ ({ (2 S) - 5-{ [ (benzyloxy) carbonyl]amino)-2- [ (tert-butoxycarbonyl) amino]pentanoyl}amino) -methyl]benzoate The target compound was obtained in a similar manner to that of Example 4 2-1. MS ( ( + ) ESI) m/z : 536 (M + Na)+. Example 116-2 Methyl 3- { f ( ( 2S) -2-amino-5-{ [ (benzyloxy) carbonyl] - amino}pentanoyl) amino]methyI}benzoate hydro chlo r i de The target compound was obtained in a similar manner to that of Example 82-1. MS ((+)ESI) m/z : 436 (M+Na)+. Examp1e 116-3 Methyl 3- { [ ( ( 2 S) - 5-{ [ (benzyloxy) carbonyl]amino)-2 -{ [ (l-methyl-lH-indol-2-yl)carbonyl]amino}-pentanoyl)amino]methyl}benzoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 593 (M+Na)+. Examp1e 117 3- { [ ( (2S)-5-{ [ (Benzyloxy) carbonyl]amino}-2-{ [ ( 1-methyl-lH-indol-2-yl) carbonyl]aminojpentanoyl) -amino]methyl}benzoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 555 (M-H)~. 2H-NMR (200MHz, DMSO-d6) : 6 1.44-1.87 (4H, m) , 3.00-3.09(2H, m) , 3.97(3H, s), 4 . 37 (2H, d, J=6.0Hz), 4.42-4.50(lH, m), 5.00(2H/ s ) , 7.08-7.89(15H, m) , 8.50-8. 60(2H, m), 12. 9 (lHr br). Examp1e 118 Methyl 3-[({(2S)-5-{[(benzyloxy)carbonyl]amino}-2-f (2-quinolinylcarbonyl) amino]pentanoyl}amino) -methyl]benzoate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 591 (M+Na)+. Example 119 3-[ ({ (2 S) -5-{ [ (Benzyloxy) carbonyl]amino}-2-[ (2-quinolinylcarbonyl)amino]pentanoyl}amino)methyl]-benzoic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 553 (M-H) '. aH-NMR (200MHz, DMSO-d6) : 5 1.45-1.59(2H, m) , 1.80-1.95(2H, m)7 3.01-3.11(2H, m), 4 . 42 (2H, d, J=5. 5Hz) , 4.62-4.72{lH, m) , 5.00(2H/ s ) , 7.25-7.57 (7H, m) , 7.71-7.93(4H, m) , 8.08-8.22 (3H, m) , 8 . 60 ( 1H, d, J=8.5Hz), 8.80-8.89<2H, m) , 12.9(1H, br). Example 12 0-1 Methyl {3-[({(2S)-5-{[(benzyloxy)carbonyl]amino)-2- [ (tert-butoxycarbonyl) amino]pentanoyl}amino) -methyl]phenyl}acetate The target compound was obtained in a similar manner to that of Example 42-1. MS ((+)ESI) m/z : 550 (M+Na)+. Example 12 0-2 Methyl (3-{[((2S)-2-amino-5-{[ (benzyloxy) - carbonyl]amino}pentanoyl)amino]methyl}phenyl)-acetate hydrochloride The target compound was obtained in a similar manner to that of Example 82-1. MS ((+)ESI) m/z : 428 (M+H)+. Example 12 0-3 Methyl ( 3-{ [ ( (2S) -5-{ [ (benzyloxy) carbonyl]amino)-2-{[(l-methyl-lH-indol-2-yl)carbonyl]amino}-pentanoyl)amino]methyl(phenyl)acetate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 607 (M+Na)+. Example 121 (3-{ [ ( (2S) -5-{ [ (Benzyloxy)carbonyl]amino}-2-{ [ (1-methyl-lH-indol-2-yl)carbonyl]amino}pentanoyl)-amino]methyl}phenyl)acetic acid The target compound was obtained in a similar manner to that of Example 28. MS ((-)ESI) m/z : 569 (M-H)'. ^-NMR (200MHz, DMSO-d6) : 8 1.40-1.88(4H, m) , 3 . 00-3 . 09 (2H, m) , 3.53(2H, s), 3.97(3H, s), 4.30(2H, d, J=6.0Hz) , 4.39-4.50(lH, m) , 5 . 00 < 2H, s ) , 7.06-7.66<15H, m), 8 . 50 (2H, d, J = 5.0Hz) , 12.3(1H, br) . Example 122 Methyl { 3 - [ ({ ( 2 S) - 5-{ [ (benzyloxy) carbonyl]amino)-2- [ (2-quinolinylcarbonyl)amino]pentanoyl}amino) -methyl]phenyl}acetate The target compound was obtained in a similar manner to that of Example 27-3. MS ((+)ESI) m/z : 605 (M+Na)+. Ex amp1e 12 3 { 3- [ ({ ( 2S) -5-{ [ (Benzyloxy) carbonyl]amino}-2- [ (2- quinolinylcarbonyl)amino]pentanoyl}amino)methyl]- phenyl(acetic acid The target compound was obtained in a similar manner to that of Example 28. MS ( ( -) E SI) m/z : 567 (M-H)". ^-NMR (200MHz, DMSO-d6) : d 1.43-1.57(2H, m) , 1.77-1.92(2H, m), 3.00-3.09(2H, m) , 3 . 54 ( 2H, s) , 4. 33 (2H, d, J=5.5Hz), 4.59-4.70 (1H, m) , 4 . 99 (2H, s), 7.12-7.32 (10H, m) , 7.70-7.93<2H, m) , 8 . 11 ( 1H, d, J = 7 . 5 Hz), 8 . 19 (2H, df J^8.5Hz), 8.60(1H, d, J=8.5Hz), 8.72-8.86(2H, m) , 12.3(1H, br). Example 12 4-1 Ethyl { 2- [({(2S)-5-{[(benzyloxy)carbonyl]amino}-2-[(tert-butoxycarbonyl)amino]pentanoyl}amino)-methyl]phenyl)acetate The target compound was obtained in a similar manner to that of Example 42-1. MS ( { + ) ESI) m/z : 564 (M + Na) + . Example 12 4-2 Ethyl (2-{ [ ( (2S) -2-amino-5-{ [ (benzyloxy) carbonyl] - aminoJpentanoyl)amino]methyl(phenyl)acetate hydro chloride The target compound was obtained in a similar manner to that of Example 82-1. MS {( + ) ESI) m/z : 442 (M + H) + . Example 12 4-3 Ethyl { 2 - { [ ( { 2 S) - 5-{ [ (benzyloxy) carbonyl]amino)-2-{[(l-methyl-lH-indol-2-yl)carbonyl]amino}-pentanoyl)amino]methyl}pheny1)acetate The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 621 (M+Na)+. Examp1e 12 5 (2-{ [ ( (2S) -5-{ [ (Benzyloxy)carbonyl]amino}-2-{ t ( 1-methyl-lH-indol-2-yl)carbonyl]amino}pentanoyl)-amino]methyl}phenyl) acetic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 569 (M-H)". XH-NMR (200 MHz, DMSO-d6) : 8 1.43-1.61 (2H, m), 1.71-1.85(2H, m) , 3.00-3.09(2H/ m) , 3.66(2H/ s), 3.97(3H, s ) , 4 . 31 (2H, d, J = 5.5Hz), 4.39-4.49(lH, m) , 5. 00 (2H, s ) , 7.07-7.33 (13H, m) , 7 . 53 ( 1H, d, J=8.5Hz), 7 . 64 (1H, d, J = 8 . 0Hz) , 8.40 (1H, t , J=6.0Hz)/ 8. 50 (1H, d, J=8.0Hz) , 12. 4 (1H, br) . Examp1e 12 6 Ethyl {2 - [ ( { (2 S) - 5-{ [ (benzyloxy) carbonyl] amino} [(2-quinolinylcarbonyl)amino]pentanoyl}amino)-methyl]phenyl } acetate -2- The target compound was obtained in a similar manner to that of Example 27-3. MS ( ( + ) ESI) m/z : 619 (M + Na) + . Examp1e 12 7 {2- [ ({ (2S)-5-{ [ (Benzyloxy)carbonyl]amino}-2-[ (2- quinolinylcarbonyl)amino]pentanoyl}amino)methyl]- phenyl[acetic acid The target compound was obtained in a similar manner to that of Example 28. MS ( (-)ESI) m/z : 567 (M-H) '. 1H-NMR (200MHz, DMSO-d6) : 5 1.41-1.56(2H, m) , 1.76-1.91 (2H, m) , 2 . 9 8 - 3 . 0 8 ( 2 H , m) , 3 . 6 7 ( 2 H , s ) , 4 . 34 ( 2H, d, J=6.0Hz), 4.58-4.69(lH, m) , 4 . 98 (2H, s ) , 7.20-7.32 (10H, m) , 7.70-7. 93(2H, m) , 8 . 10 ( 1H, d, J=7.5Hz), 8 . 18 (2H, d, J=8.5Hz)/ 8.58-8.68(2H, m) , 8. 8 3 ( 1H, d, J = 8 . 5Hz) , 12 . 4 ( 1H, br). Example 128 (5-Methyl-2-oxo-l,3-dioxol-4-yl)methyl 6- [ ( (2S)~ 2 - [ (l-benzofuran-2-ylcarbonyl)amino] -5-{ [ (benzyl-oxy)carbonyl]amino}pentanoyl)amino]hexanoate To a solution of sodium 6-[[(2S)-2-[(l-benzofuran-2-ylcarbonyl)amino]-5-[[(benzyloxy)-carbonyl]amino]pentanoyl]amino]hexanoate (15 Omg) in N/N-diiriethylacetamide (1.5mL), was added 4- (bromomethyl) -5-methyl-l, 3-dioxol-2-one (37.5// L) . The mixture was stirred at room tempe rature for 20 hours. The mixture was diluted with water (lOmL) and extracted with ethyl acetate (lOmL) . The organic layer was washed with water (10mL><2) and brine (lOmL), and dried over magnesium sulfate. Filtration followed by evaporation gave the target compound (93mg) as a white solid. MS ( ( + ) ESI) m/z : 658 (M + Na) + . 1H-NMR(200MHz,DMSO-d6) : 8 1.17-1.82 (10H, m) , 2.14 (3H, s ) , 2 . 33 ( 2H, t , J=7.0Hz), 2.97-3.10(4H, m) , 4.35-4.46(lH, m) , 4 . 93 (2H, s), 5 . 00 (2H, s ) , 7 . 22-7 . 52 ( 8H, m), 7.63(1H, s), 7.68(1H, d, J=8.5Hz), 7.78(19, d, J=7 . 0Hz) , 8 . 03 <1H, t, J=5.5Hz)/ 8 . 50 ( 1H, d, J=8.0Hz). Example 12 9 [ (2, 2-Dimethylpropanoyl) oxy]methyl 6- [ ( (2S) -2- [ ( 1-benzofuran-2-ylcarbonyl)amino]-5-{[(benzyloxy)-carbonyl]amino}pentanoyl)amino]hexanoate The target compound was obtained in a similar manner to that of Example 128. MS ( ( + )ESI) m/z : 660 (M+Na)+. 2H-NMR (200MHz, DMSO-d6) : 5 1 . 13 ( 9H, s) , 1 . 20-1. 80 (10H, m) , 2.34(2H, t, J=7.0Hz), 2.96-3.10(4H, m) , 4.35-4.46(lH, m) f 5.00(2H, s ) , 5. 68 (2H, s ) , 7.24-7.52(8H, m) , 7.62(1H, s ) , 7. 69 ( 1H, d, J=8.5Hz) , 7.78(1H, d, J=7.0Hz), 8 . 03 ( 1H, t , J=5.5Hz) , 8 . 50 (1H, d, J=8.0Hz). Ex amp 1e 13 0 l-{ [ (Cyclohexyloxy) carbonyl]oxy)ethyl 6 - [ ( ( 2 S ) -2 - [ (l-benzofuran-2-ylcarbonyl) amino]-5-{ [ (benzyloxy) carbonyl]amino}pentanoyl)amino]hexanoate The target compound was obtained in a similar manner to that of Example 128. MS ((+)ESI) m/z : 716 (M+Na)+. 2H-NMR (200MHz, DMSO-d6) : 5 1.16-1.87 (23H, m), 2 . 31 (2H, t , J = 7.0Hz) , 2.96-3.09(4H, m) , 4.33-4.63(2H, m), 5 . 00 ( 2H, s), 6.62(1H, q, J = 5 . 0Hz) , 7.24-7.52(8H, m), 7.62(1H, s), 7 . 69 (1H, d, J=8.5Hz), 7.78 (1H, df J = 7.5Hz), 8.03(1H, t, J=5.5Hz), 8.50(1H, d, J=8.0Hz). Ex amp 1e 13 1 Methyl 3 - { 2 - [ ( ( 2 S) - 5- { [ (benzyloxy) carbonyl] amino}-2-{[(l-methyl-lH-indol-3-yl)carbonyl]amino}-pentanoyl)amino]phenyl}propanate To a solution of methyl 3-[2-[[(2S)-2- amino-5- [ [ (benzyloxy) carbonyl]amino]pentanoyl] - amino]phenyl]propanoate hydrochloride (208mg) and 1-hydroxybenzotriazole ( 1 6 Omg) in N,N-dimethylformamide ( 5 . OmL) , was added 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (184mg) at 5 t under nitrogen. The mixture was stirred at room temperature for 12 hours. The resulting mixture was poured into water and the aqueous layer was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium bicarbonate three times and brine, dried over anhydrous magnesium sulfate, and evaporated under reduced pressure. The residue was purifiedby column chromatographyon silica gel (hexane / ethyl acetate = 1 : 1 to 1 : 2) to give the target compound (357mg). MS ( ( + ) ESI) m/z : 607 (M + Na) + . Examp1e 13 2 3-{2-[ ( (2S)-5-{ [ (Benzyloxy)carbonyl]amino}-2-{ [ (1 -methyl-lH-indol-3-yl)carbonyl]amino}pentanoyl)-amino]phenyl}propanoic acid To a solution of methyl 3- [ 2- [ [ (2S) -5- [ [ (benzyloxy)carbonyl]amino]-2-[ [ ( 1 -methyl-lH-indol-3-yl) carbonyl]amino]pentanoyl] -amino]phenyl]propanoic acid (355mg) obtained in Example 131 in 1,4-dioxane (lOmL), was added IN sodium hydroxide (1.82mL) at room temperature. The mixture was stirred at 45 *C for 2.5 hours. The resulting mixture was poured into IN hydrochloric acid and the aqueous layer was extracted with a mixture of chloroform and methanol (5:1). The organic layer was dried over anhydrous magnesium sulfate, evaporated, and dried in vacuo to give the target compound (373mg) . MS ( (-)ESI) m/z : 569 (M-H)". 2H-NMR (DMSO-d6) : 8 1 . 5 - 1 . 9 5 ( 4 H , m), 2.4-2.5(2H, m), 2.75-2.9(2H, m), 3.0-3.15(2H, m) , 3.84(3H, s), 4 . 6-4 . 8 (1H, m) , 5. 00 (2H, s), 7.05-7.55(llH, m), 7.95-8.05(lH, m) , 8 . 1 -8 . 1 ( 2H, m). Examp1e 13 3 Methyl 3-{2-[ ( (2S) -5- { [ (benzyloxy)carbonyl]amino}-2 - { [ (l-methyl-lH-indazol-3-yl)carbonyl]amino}-pentanoyl)amino]phenyl(propanoate The target compound was obtained in a similar manner to that of Example 131. MS ( ( + )ESI) m/z : 608 (M + Na) + . Examp1e 13 4 3- { 2- [ ( < 2S)-5-{ [ (Benzyloxy) carbonyl]amino}-2-{ [ (1-methyl-lH-indazol-3-yl)carbonyl]aminojpentanoyl)-amino]phenyl}propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ( (-)ESI) m/z : 570 (M-H)". 3H-NMR (DMSO-d6) : 8 1.45-1. 65 (2H, m) , 1 . 85-2. 0(2H,m), 2. 4-2 . 5 (2H, m), 2.75-2.9(2H, m), 3.0-3.15(2H, m) , 4 . 15 (3H, s ) , 4.7-4.95 (1H, m), 4 . 99 <2H, s), 7.1-7.55(10H, m), 7 . 7-7 . 8 ( 1H, m), 8 . 1-8 . 5 (2H, m) . Example 13 5 Methyl 3 - { 2 - [ ( {2S) - 5-{ [ (benzyloxy)carbonyl]amino)- 2-{[(8-methylimidazo[l,2-a]pyridin-2-yl)carbonyl]-amino}pentanoyl) ami no]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 131. MS ((+)ESI) m/z : 608 (M+Na)+. Examp1e 13 6 3-{2-[ ( (2S) -5-{ [ (Benzyloxy)carbonyl]amino}-2-{ [ (8-methylimidazo[1,2-a]pyridin-2-yl)carbonyl]amino}-pentanoyl)amino]phenyl}propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ((-)ESI) m/z : 570 (M-H)'. 2H-NMR (DMSO-de) : 5l.5-2.0(4H, m), 2.4-2.5(2H, m), 2.58(3H, s), 2.75-2.9(2H, m), 3.0-3.2(2H/ m), 4.75-4.9(lH, m) , 5 . 00 ( 2H, s ) , 7.1-7.55 (10H, m) , 8.6-8.9(3H, m). Examp1e 13 7 Methyl 3- (2 -{ [ (2S) - 5-{ [ (benzyloxy) carbonyl]amino)- 2- (2-naphthoylamino)pentanoyl]amino}phenyl) - pr op anoa t e The target compound was obtained in a similar manner to that of Example 131, MS ((+)ESI) m/z : 604 (M+Na)+. Examp1e 13 8 3- {2 -{ [ (2 S ) - 5 -{ [ (Benzyloxy) carbonyl]amino)-2- ( 2 - naphthoylamino)pentanoyl]amino}phenyl)propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ( (-) ESI) m/z : 566 (M-H)". :H-NMR (DMSO-d6) : 8 1.5-1.75(2H, m), 1 . 8 - 2 . 0 ( 2 H , m), 2.45-2.6(2H, m) , 2.75-2.9(2H, m) , 3.05-3.2 (2H, m) , 4.6-4.8(1H, m) , 5 . 01 (2H, s ) , 7.1-7.45(9H, m) , 7.55-7.7 (2H, m) , 7 . 9-8 . 1 (4H, m) , 8 . 56 ( 1H, s). Example 139 Methyl 3-[2-({ ( 2S) - 5-{ t (benzyloxy)carbonyljamino}- 2- [ (3-quinolinylcarbonyl) amino]pentanoyl}amino) - phenyl]propanoate The target compound was obtained in a similar manner to that of Example 131. MS ( ( + ) ESI) m/z : 605 (M + Na) + . Example 14 0 3- [ 2- ( { ( 2S) -5-{ [ (Benzyloxy)carbonyl]amino}-2-[ (3- quinolinylcarbonyl)amino]pentanoyl}amino)phenyl]- propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ((-)ESI) m/z : 567 (M-H)". 2H-NMR (DMSO-d6) : 8 1.5-2.1(4H, m), 2.35-2.6(2H, m), 2 . 7-2 . 9 ( 2H, m) , 2.95-3.2(2H/ m) , 4 . 6-4 . 8 ( 1H, m) , 5. 01 (2H, s ) , 7.05-7.5(9H, m) , 7.65-7.75(lH, m) , 7.8-7.95(lH,m), 8.05-8.2(2H,m), 9.04(1H/ s) , 9. 35 ( 1H, m) . Ex amp 1e 14 1 Methyl 3- [ 2- { { ( 2S) -5-{ [ (benzyloxy) carbonyl]amino}-2- [ (3-isoquinolinylcarbonyl) amino]pentanoyl}-amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 131. MS (<+)ESI) m/z : 605 (M+Na)+. Example 14 2 3- [2 - ( { (2S ) - 5-{ [ (Benzyloxy)carbonyl]amino}-2 isoquinolinylcarbonyl)amino]pentanoyl}amino) phenyl]propanoic acid - [ (3- The target compound was obtained in a similar manner to that of Example 132. MS ( ( - ) ESI ) m/z : 567 (M-H) ". ]H-NMR (DMSO-d6) : 5l.5-1.7(2H, m), 1.8-2.05(2H, m) , 2,4-2. 55(2H/ m), 2,75-2. 9<2H, m) , 3. 0-3 . 2 (2H, m), 4.8-4.95(lH, m) , 4 . 98 (2H, s ) , 7.1-7.45(9H, m) , 7.75-7.95(2H7 m) , 8.15-8.35(2H, m) , 8.61(1H, s), 9.7 9 ( 1H, s ) . Examp1e 14 3 Methyl 3- [2- ( { (2S ) - 5-{ [ (benzyloxy) carbonyl]amino}-2-[(2-quinoxalinylcarbonyl)amino]pentanoyl}amino)-phenyl]propanoate The target compound was obtained in a similar manner to that of Example 131. MS ((+1ESI) m/z : 606 (M+Na)+. Example 14 4 3- [2- ({ (2S)-5-{ [ (Benzyloxy)carbonyl]amino}-2-[ (2-quinoxalinylcarbonyl)amino]pentanoyl}amino)-phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ( (-)ESI) m/z : 568 (M-H) ". ^-NMR (DMSO-d6) : 5 1 . 5-1 . 7 (2H, m) , 1.85-2.1 (2H, m) , 2 . 4-2 . 5 (2H, m), 2.75-2.9(2H, m) , 3.05-3.2 (2H, m) , 4.75-4.9(lH, m) f 4.99(2H, s), 7.1-7. 45(9H, m) , 7.95-8.05(2H, m), 8.2-8.35(2H, m), 9.51(1H, s). Example 14 5 Methyl 3 -[2 - ( { ( 2 S) - 5-{ [ (benzyloxy)carbonyl]amino}-2- [ (4-quinolinylcarbonyl) amino]pentanoyl}amino) -phenyl]propanoate The target compound was obtained in a similar manner to that of Example 131. MS ((+)ESI) m/z : 605 (M+Na)+. Ex amp 1e 14 6 3-[2-({ ( 2S)-5- { [ (Benzyloxy)carbonyl]amino}-2-[ (4-quinolinylcarbonyl) amino]pentanoyl}amino)phenyl] -p ropano i c acid The target compound was obtained in a similar manner to that of Example 132. MS ( (-)ESI) m/z : 567 (M-H)'. aH-NMR (DMSO-d6) : 8 1.55-2.0(4H, m), 2.45-2.6(2H, m), 2.8-2.95(2H, m) , 3.05-3.2(2H, m) , 4.65-4.8 (1H, m) , 5. 01 (2H, s) , 7.1-7.4(9H, m) , 7.55-7.7(2H, m) , 7.75-7.9(lH, m) , 8,05-8. 1 (1H, m), 8.2-8.25(lH, m) , 8 . 95-9 . 0 (1H, m) . Example 14 7 Methyl 3-[2-({ (2 S) -5-{ [ (benzyloxy) carbonyi]araino}-2 - [ (1-isoquinolinylcarbonyl)amino]pentanoyl}-amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 131. MS ( ( + JESI) m/z : 605 (M + Na)+. Example 14 8 3- [ 2 - ( { (2S)-5-{ [ (Benzyloxy)carbonyl]amino}-2-[ (1-isoquinolinylcarbonyl)amino]pentanoyl}amino)-phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ((-)ESI) m/z : 567 (M-H)". !H-NMR (DMSO-d6) : 8 1.5-2.05(4H, m) , 2.4-2.55(2H, m) , 2.75-2,9(2H, m) , 3.05-3.2 (2H, m) , 4 . 7-4 .9 ( 1H, m) , 4.99{2H, s) , 7.1-7.45(9H, m) , 7 . 7-7 . 9 (2H, m) , 8 . 0-8 . 1 (2H, m) , 8.55~8.6(1H, m) , 8.95-9.05(lH, m) . Example 14 9 Methyl 3-{2-[ ( ( 2 S ) - 5- { [ (benzylox.y) carbonyi] amino]-2-{ [5-(4-chlorophenyl) -2-furoyl]amino}pentanoyl) -amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 131. MS ((+)ESI) m/z : 654, 656 (M+Na)+. Example 150 3- { 2- [ ( (2S) -5-{ [ (Benzyloxy)carbonyl]amino}-2-{ [ 5-(4-chlorophenyl)-2-furoyl]amino}pentanoyl)amino]-phenyl}propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS (<-)ESI) m/z : 616, 618 (M-H)". ]H-NMR (DMSO-d6) : 5 1 . 5-2 . 0 ( 4H, m), 2.45-2.55(2H, m) , 2.75-2.9(2Hf m) f 3 . 0-3 . 2 (2H, m) , 4.6-4.75(lH, m), 7.1-7.4 (11H, m) , 7.5-7.6(2H, m) , 7. 9-8 . 0 (2H, m) . Examp1e 15 1 Methyl 3-[2-({(2S)-5-{[(benzyloxy)carbonyl]amino}-2-[(2-biphenylylcarbonyl)amino]pentanoyl}amino)-phenyl]propanoate The target compound was obtained in a similar manner to that of Example 131. MS ((+)ESI) m/z : 630 (M+Na)+. Examp1e 15 2 3-[2-({ (2S)-5-{ [ (Benzyloxy)carbonyl]amino}-2-[ (2-biphenylylcarbonyl)amino]pentanoyl}amino)phenyl]-propanoic acid The target compound was obtained in a similar manner to that of Examp1e 13 2. MS ( (-)ESI) m/z : 592 (M-H) ". aH-NMR (DMSO-d6) : 5 1.2-1.8(4H, m) , 2.4-2.55(2H, m) , 2.7-2.85(2H, m), 2.9-3.05(2H, m) , 4.35-4.5(lH, in), 5. 02 (2H, s ) , 7.1-7. 6(18H, m). Examp1e 15 3 Methyl 3- [2- ( { (2S)-5-{ [ (benzyloxy) carbonyl]amino}-2-[ (4-phenoxybenzoyl) amino]pentanoyl}amino) -phenyl]propanoate The target compound was obtained in a similar manner to that of Example 13 1. MS ((+)ESI) m/z : 646 (M+Na)+. Ex amp 1e 15 4 3- [ 2- ( { ( 2S) - 5-{ [ (Benzyloxy)carbonyl]amino}-2-[ ( 4-phenoxybenzoyl)amino]pentanoyl}amino)phenyl]-pr opa noic acid The target compound was obtained in a similar manner to that of Example 132. MS ( (-)ESI) m/z : 608 (M-H)'. ^-NMR (DMSO-d6) : 5 1. 45-1. 7(2H,m),l.75-1. 95(2H,m), 2 . 4-2 . 6 (2H, m) , 2.75-2.9<2H, m) , 3 . 0-3 . 2 (2H, m) , 4 . 5-4 .7 ( 1H, m), 5 . 00 (2H, s ) , 7.0-7. 5 ( 16H, m) , 7 . 9-8 . 0 (2H, m). Ex ample 15 5 Methyl 3- [2 - ({ (2S) -5-{ [ (benzyloxy) carbonyl]amino}-2-[(3,4-dimethoxybenzoyl)aminojpentanoyl}amino)-phenyl]propanoate The target compound was obtained in a similar manner to that of Example 131. MS ((+)ESI) m/z : 614 (M+Na)+. Example 15 6 3-[2-({ ( 2S) - 5-{ [ (Benzyloxy)carbonyl]amino}-2-[(3,4-dimethoxybenzoyl)aminojpentanoyl}amino)-phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ( (-)ESI) m/z : 576 ( M-H)'. aH-NMR (DMSO-d6) : 5 1.45-1.7 (2H, m) , 1.75-2.0(2H, m) , 2.4-2.55(2H, m) , 2.75-2.9(2H, m) , 3.0-3.2(2H, m) , 3. 81 ( 6H, s ) , 4.55-4.75(lH, m) , 5.00(2H, s ) , 7.0-7.45<10H, m) , 7.5-7.65(2H, m). Examp1e 15 7 Methyl 3-{2- [ ( (2S) -5-{ [ (benzyloxy) carbonyl]-amino}-2-{[(6-methyl-2-pyridinyl)carbonyl]amino}-pentanoyl)amino]phenylJpropanoate The target compound was obtained in a similar manner to that of Example 131. MS ((+)ESI) m/z : 569 (M+Na)*. Examp1e 15 8 3- { 2 - [ ( (2S)-5-{ [ (Benzyloxy)carbonyl]amino}-2- { [ (6-methyl-2-pyridinyl) carbonyl]aminojpentanoyl) - amino]phenyl}propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ('(-)ESI) m/z : 531 (M-H)'. 2H-NMR (DMSO-d6) : 5 1.4-1.65(2H, m) , 1 . 7-2 . 0 (2H, m) , 2.4-2.55(2H, m) , 2 . 57 (3H, s)f 2.75-2.9(2H, m) , 3.0-3.15(2H, m) , 4 .7-4 . 9 (1H, m) , 4 . 99 (2H, m) , 7.1-7.55(10H, m) , 7.85-7.95(2H, m) . Example 159 Methyl 3- [ 2 - ( { (2 S) - 5- { [ (benzyloxy) carbonyljamino)-2- [ (3, 4-dimethylbenzoyl) amino]pentanoyl}amino) -phenyl]propanoate The target compound was obtained in a similar manner to that of Example 131. MS ( ( + )ESI) m/z : 582 (M + Na) + . Examp1e 16 0 3-[2 - ( { (2S) - 5-{ [ (Benzyloxy) carbonyl]amino}-2-[ (3, 4-dimethylbenzoyl) amino]pentanoyl}amino) -phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ( (-)ESI) m/z : 544 (M-H) ". 2H-NMR (DMSO-d6) : 5 1.45-1.7 (2H, m) , 1.75-1.95(2H,m), 2.27(6H, s) , 2 . 4-2 . 5 (2H, m) , 2.75-2.9(2H, m) , 2.95-3.15(2H, m) , 4 . 5-4 . 7 (1H, m) , 5 . 00 (2H, s ) , 7.05-7.45(10H/ m) , 7. 6-7 . 8 (2H, m) . Examp1e 16 1 Methyl 3- [2- ( { {2 S) -5-{ [ (benzyloxy) carbonyl]amino}-2- [ (3, 4-dichlorobenzoyl) amino]pentanoyl}amino) -phenyl]propanoate The target compound was obtained in a similar manner to that of Example 131. MS ( ( + ) ESI) m/z : 622, 624 (M + Na)Example 16 2 3- [ 2- ( { (2S) -5-{ [ (Benzyloxy)carbonyl]amino}-2-[ (3, 4-dichlorobenzoyl) amino]pentanoyl}amino) -phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ( (-) ESI) m/z : 584, 586 (M-H)~. ^-NMR (DMSO-d6) : d 1.45-1.7(2H,m), 1.75-1.95(2H,m), 1.4-1.55(2H, m) , 2.75-2.9 (2H, m), 3.0-3.15(2H, m) , 4 . 5-4 .7 (1H, m) , 5.01(2H, s ) , 7.1-7.4(9H, m) , 7.76(1H/ d, J = 8.3Hz), 7 . 91 ( 1H, dd, J=l . 9, 8 . 4Hz ) , 8 . 20 ( 1H, d, J=l. 9Hz) . Example 16 3 Methyl 3-[2-({(2S)-5-({[(2-chlorobenzyl)oxy]- carbonyl}amino)-2-[(lH-indol-2-ylcarbonyl)amino]- pentanoyl}amino)phenyl]propanoate The target compound was obtained in a similar manner to that of Example 131. MS ((-)ESI) m/z : 603, 605 (M-H)". Ex amp 1e 16 4 3-[2-({(2S)-5-({[(2-Chlorobenzyl)oxy]carbonyl}- amino)-2-[(lH-indol-2-ylcarbonyl)amino]pentanoyl}- amino)phenyl]propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ((-)ESI) m/z : 589, 591(M-H)~. XH-NMR (DMSO-d6) : 8 1.5-2.0(4Hr m), 2.4-2.6(2H, m), 2.75-2.9(2H, m) , 3.0-3.2(2Hf m) , 4 . 6-4 . 8 ( 1H, m) , 5.09(2H, s) , 7.0-7.55(12H, m) , 7.62(1H/ d, J=7 . 8 Hz). Example 16 5 Methyl 3-{2-[((2S)-5-({[(2-chlorobenzyl)oxy]- carbonyljamino) -2-{ [ (l-methyl-lH-indol-2-yl)- carbonyl]amino}pentanoyl)amino]phenyl}propanoate The target compound was obtained in a similar manner to that of Example 131. MS ( ( + ) ESI) m/z : 64 1, 643 (M + Na) + . Examp1e 16 6 3- { 2- [ ( (2S)-5- ({ [ <2-Chlorobenzyl)oxy]carbonyl}-amino)-2-{[(l-methyl-lH-indol-2-yl)carbonyl]-aminojpentanoyl)amino]phenyl(propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ((-)ESI) m/z : 603,605 (M-H)~. !H-NMR (DMS0-d6) : 5 1.45-2. 05(4H, m), 2.3-2. 6 (2H, m), 2.75-2.9(2H, m), 3.0-3.2(2H, m), 3.98(3H, s), 4.5-4.7(lH, m), 5.09(2H, s), 7.05-7.7{13H, m). Example 16 7 Methyl 3-(2-{[(2S)-2-[(4-biphenylylcarbonyl)- amino] -5- ( { [ (2-chlorobenzyl)oxy] carbonyl(amino) - pentanoyl]amino}phenyl)propanoate The target compound was obtained in a similar manner to that of Example 131, MS ((+)ESI) m/z : 664, 666 (M+Na)+. Example 168 3-(2-{ [ (2S)-2-[ (4-Biphenylylcarbonyl)amino]-5- ({[(2-chlorobenzyl)oxy]carbonyl}amino)pentanoyl]- amino}phenyl)propanoic acid The target compound was obtained in a similar manner to that of Example 132. MS ((«)ESI) m/z : 626, 628 (M-H)". ^-NMR (DMSO-de) : 6l.5-2.0(4H, m), 2.4-2. 6 (2H, m), 2.75-2.9(2H, m), 3.05-3.2 (2H, m) , 4.55-4.75(lH, m), 5.09(2H, s ) , 7.1-7.6(llH,m), 7.7-7.85(4H, m), 8 . 03 (2H, d, J=8.3Hz). Example 169-1 Ethyl 2 ' -nitro-3-biphenylylcarboxylate To a solution of l-iodo-2-nitrobenzene (2.0g) and [3-(ethoxycarbonyl)phenyl]boronic acid (2.0g) in 1,2-dimethoxyethane (20mL), were added tetrakis(triphenyl)palladium(0) (0.93g) and 2M sodium carbonate ( 8 . 4mL) at room temperature. The mixture was stirred at 80ºC for 18 hours. The resulting mixture was poured into water and the aqueous layer was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane / ethyl acetate = 10 : 1 to 5 : 1) t o give the target compound (1.2g) . MS ((+)ESI) m/z : 294 <2) for 1 hour to remove Fmoc group. Then, the solvent was drained, washed well subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure to give 6-aminohexanoic acid loaded wang resin (Theoretical loading, 0.74 mmol/g) . To a suspension of the above 6 - aminohexanoic acid loaded wang resin ( 2 . 5 5g, 1.89mmo1) and ( 2 S) -5- (benzyloxycarbony) amino-2- (9-fluorenyl-methoxycarbonylamino)pentanoic acid (2.77g, 5.67mmol) in NMP (25mL), was added HATU (2.15g, 5.67mmol) and DIEA (2.02mL/ 11.34mmol) . The mixture was shaken for 24 hours at room temperature. The solvent was drained, washedwell subsequently with DMF, MeOH, DCM, Et20, and dried under reducedpressure. The resulted resin was treated with 20% piperidine in DMF (25mLX2) for 1 hour to remove Fmoc group. Then, the solvent was drained, washedwell subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure to the target compound. Example 2 4 9-2 6- [ ( ( 2S) -5-{ [ (Benzyloxy)carbonyl]amino}-2-{ [ (2-naphthyloxy)carbonyl]aminoJpentanoyl)amino]-hexanoic acid To a suspension of 6 - [ ( {2 S) - 5 -{ [ (benzyloxy)-carbonyl]amino}-2-amino} pentanoyl)amino]hexanoic acid loaded wang resin (1.89mmol) obtained in Example 249-1 and pyridine (917.2 //L, 11. 34mmol) in DCM (25mL), was added 2-naphthyl chloroformate {1. 17 g, 5 . 6 7mmo 1) . The mixture was shaken for 2 days at room t empe r a tur e. The solvent was drained, washed well subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure. After treated with 50% TFA in DCM (20mL) for 1 hour, the resin was filtered and washed with DCM (15mL X 2 ) . The filtrates were combined, evaporated and purified by HPLC (reverse phase C18/ 5 µ , 30mm X50mm column, 2 54nm, gradient 10-90% 0.05% TFAinCH3CN / 0,05% TFA in H2O, 40mL/min.) . The fractions containing the target compound were combined, evaporated, and dried under reduced pressure to give the target compound. MS { ( + ) E SI) m/z : 572 ( M + N a ) + . 2H-NMR (DMSO-d6) : 5 1 . 20-1 . 70 ( 10H, m), 2. 19 (2Hf t , J=7 . 3Hz) , 2.95-3.15(4H, m) , 3.90-4.05(lH, m) , 5. 02 (2H, s) , 7.25-7.65(10H,m), 7.85-8.05(5H,m), 12 . 02 ( 1H, s). Example 2 5 0 6- ({ (2S)-5-{ [ (Benzyloxy)carbonyl]amino}-2-[ ( 4- biphenylylsulfonyl)amino]pentanoyl}amino)hexanoic acid To a suspension of 6-[ ( (2S) -5-{ [ (benzyloxy) carbonyl]amino}-2-amino} pentanoyl)amino]hexanoic acid loaded wang resin (1.8 9mmo1) obtained in Example 249-1 and pyridine ( 91 7 . 2 v L, 11.34mmol) in DCM (25mL) , was added 4-biphenylsulfonyl chloride ( 1 . 4 3 g , 5.67mmol) . The mixture was shaken for 2 days at room tempe ra t ur e . The solvent was drained, washed well subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure. After treated with 50% TFA in DCM (20mL) for 1 hour, the resin was filterd and washed with DCM (15mL X 2) . The filtrates were combined, evaporated, and purified by HPLC (reverse phase C18 , 5 µ , 3 0 mm X50mm column, 254nm, gradient 10-90% 0.05%TFAinCH3CN / 0.05% TFA in H20, 40mL/min.) . The fractions containing the target compound were combined, evaporated and dried under reduced pressure to give the target compound. MS ( (-)ESI) m/z : 594 (M-H)~. XH-NMR (DMSO-d6) : 8 1 . 10-1 . 50 (10H, m), 2.09(2H, t, J=7.3Hz), 2.70-2.85(2H, m), 2.85-3.00(2H, m), 3.55-3.75(lH, m), 4.98(2H, s), 7.20-7.55(9H, m), 7.65-8.00(8H, m), 11 . 99 <1H, br-s). Examp1e 2 51 6- [ ( (2S) -5-{ [ (Benzyloxy) carbonyl]amino}-2-{ [ ( 4 ' -hydroxy-4-biphenylyl)carbonyl]aminojpentanoyl)-amino]hexanoic acid To a suspension of 6-[((2S)-5-{[(benzyloxy)-carbonyl]amino}-2-amino} pentanoyl)amino]hexanoic acid loaded wang resin (1.89mmol) obtained in Example 249-1, 4-(4-hydroxyphenyl)benzoic acid ( 1 - 2 1 g , 5.67mmol) and HATU (2.15g, 5.67mmol) in NMP (2 0mL) , was added DIEA ( 2.0 2mL, 11.3 4mmo 1) . The mixture was shaken for 2 days at room t empe r a tur e. The solvent was drained, washed well subsequently with DMF, MeOH , DCM, Et20, and dried under reduced pressure. After treated with 50% TFA in DCM (20mL) for 1 hour, the resin was filterd and washed with DCM (15mL X 2 ) . The filtrates were combined, evaporated and purified by HPLC (reverse phase C18, 5 u , 3 0 mm X50mm column, 254nm, gradient 10-90% 0.05% TFAinCH3CN / 0,05% TFA in H20, 40mL/min.). The fractions containing the target compound were combined, evaporated, and dried under reduced pressure to give the target compound. MS ((-)ESI) m/z : 574 (M-H)". !H-NMR (DMSO-d6) : 5l.20-1.80(10H, m), 2.18(2H, t, J = 7 . 3 Hz) , 2.95-3.15(4H,m), 4.30-4.45(lH,m), 5 . 00 (2H, s), 6.87(2H, d, J=8,6Hz), 7.20-7.35(6H, m), 7.57(2H, d, J=8.6Hz), 7.67(2H, d, J=8.3Hz), 7.94(2H, d, J=8.3Hz), 8.37(1H, d, J=8.0Hz),9.66(lH, s), 12.00(1H, br-s). Example 252-1 3- { 2- [ ( (2S)-2-Amino]-5-{ [ (4-methylphenyl)diphenyl-methyl]amino Jpentanoyl) amino]phenylJpropanoic acid loaded resin To a suspension of 4- (4-formyl-3-methoxyphenoxy)-butylyl AM resin ( 1 8 g , 0.5 lmitio 1 e / g ) in a mixture of THF (200mL) and MeOH (5mL) , was added NaBH4 (695mg, 18 . 37mmol) . The mixture was shaken for 2 4 hours at room t empe rature. The resin was collected by filtration, washed well subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure. To the suspension of the above resin, 2-nitrocynnamic acid (2.66g, 13.7 7mmol) and triphenylphpsphine (3.61g, 13.77mmol) inTHF (200mL), was added DEAD (2.17mL, 13.7 7mmol) . The mixture was shaken for 24 hours at room temperature. After drained the solvent, the resin was washed well with THF, and the carboxylic acid loading reaction was repeated. The resin was collected by filtration, washed well subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure. After treatment with a mixture of Ac20 (17.36mL, 18.3 6mmol) and pyridine (29.7mL, 36.7 2mmo1) in DCM (200mL) for 24 hours at room temperature, to the resulted resin was added 2M SnCl2-H20 in DMF (150mL X2) for 2 hours. Then, the resin was collected by filtration, washed well subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure to give 2-aminocinnamic acid loaded resin. To a suspension of the above 2-aminocinnamic acid loaded resin (9.18mmol) and (2S) -2- (9-fluorenylmethoxycarbonyl) amino-5-{ [ ( 4 -me thylphenyl)diphenylmethyl]amino}pentanoic acid (16. 8g, 27.54mmol) and PyBroP (12.84g, 27.54mmol) in DMF (200mL), was added DIEA (9, 8 3mL , 55. 08 mm ol). The mixture was shaken for 2 days at room temperature. The resin was collected by filtration, washed well subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure. After the removal of Fmoc group with 20% piperidine in DMF (150mL><2) for 1 hour, the resin was collected by filtration, washed well subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure to give the target compound. Example 252-2 3-{2-[ ( (2S)-2-[ (l-Benzofuran-2-ylcarbonyl)amino]-5 - { [ (benzyloxy) carbonyl] amino}pentanoyl) amino] -phenyl}propanoic acid To a suspension of 3-{2-[((2S)-2-amino]-5-{[(4-methylphenyl)diphenylmethyl]aminolpentanoyl)-amino]phenyl}propanoic acid loaded resin (4.59mmol) obtained in Example 252-1, 1 -benzofuran - 2 -carboxy1ic acid (2.24g, 13.77mmol) and HATU (5.24g, 13.77mmol) in NMP (lOOmL), was added DIEA (4.92mL, 27.54mmol). The mixture was shaken for 4 days at room temperature. The resin was collected by filtration, washed well subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure. After treated with 5% TFA in DCM (lOOmL) for 1 hour, the resin was filterd and washed with DCM ( 5 0mL X 2) . The filtrates were combined, evaporated and purified by HPLC (reverse phase C1Q, 5 ii , 3 0 mm X 5 0 mm column, 254nm, gradient 10-90% 0.1% TFA in CH3CN / 0.1% TFA in H20, 40mL/min.) . The fractions containing the target compound were combined, evaporated, and dried under reduced pressure to give 3- { 2- [ ( (2S) -2- [ (l-Benzofuran-2-ylcarbonyl) amino] -5-aininopentanoyl) amino] phenyl}propanoic acid (200mg). A mixture of the above 3- { 2- [ ( (2S) -2- [ (l-Benzofuran-2-ylcarbonyl) amino] -5-aminopentanoyl)amino] phenylJpropanoic acid (190mg, 0 . 4 5mmo 1) and 10% palladium on carbon (50% wet, 20mg) in MeOH ( 5mL) was hydrogenated at atmospheric pressure of hydrogen at room temperature. After 4 hours, the catalyst was removed by filtration and evaporated to give residue, which was dissolved in DCM (30mL) . To the resulting mixture was added 1-(benzyloxycarbonyloxy)benzotriazole-6-carboxamid omethyl polystyrene ( 2.4 2 g, 0.9 3mmole/g) and shaken for 1 week at room temperature. The resin was removed by filtration and evaporation of the solvent gave a residue , which was purified by HPLC (reverse phase Ci8/ 5ji , 3 0mm X 5 0mm co lumn , 254nm, gradient 10-90% 0.1% TFA in CH3CN / 0.1% TFA in H20, 4 OmL/mi n . ) . The fractions containing the target compound were combined, evaporated, and dried under reduced pressure to give the target compound (63.2mg), MS ( (-)ESI) m/z : 556 (M-H) ~ . aH-NMR (DMSO-de) : 5 1 . 45 - 2. 05 ( 4H, m), 2. 40 - 2 . 55 (2H, m), 2 . 81 (2H, t, J=7.5Hz), 3.00-3.15(2H, m) , 4.60-4.75(lH, m), 5.00(2H, s ) , 7.15-7.55(12H, m), 7. 65-7 . 85 (3H, m), 8.75(1H, d, J=7.7Hz), 9.60(1H, S), 12 . 15 (1H, br-s ) . Examp1e 2 5 3 3-{2 - [ ( (2S) -5-{ [ (Benzyloxy)carbonyl]amino}-2-{ [ (4-biphenylylamino)carbonyl]amino}pentanoyl)amino]-phenyl}propanoic acid A suspension of 3-{2-[((2S)-2-amino]-5-{ [ (4-methylphenyl) diphenylmethyl]amino}pentanoyl) -amino]phenyl}propanoic acid loaded resin (4.5 9 mmo1) obtained in Example 252-1 and 4-biphenylyl isocyanate (2.69g, 13. 77 mm ol) in DCM '( l00mL) was shaken for 4 days at room temperature. The resin was collected by filtration, washed well subsequently with DMF, MeOH, DCM, Et20, and dried under reduced pressure. After treated with 5% TFA in DCM ( 1 OOmL) for 1 hour, the resin was filtered, and washed with DCM (50mL X 2) . The filtrates were combined, evaporated, and purified by HPLC (reverse phase C18, 5 X , 30mmX50mm column, 254nm, gradient 10-90% 0.1% TFA in CH3CN / 0.1% TFA in H20, 40mL/min.). The fractions containing the desired compound were combined, evaporated, and dried under reduced pressure to give 3 -{2 -[ ( (2S)-5-amino-2-{ t (4-biphenylylamino) carbonyl]aminolpentanoyl) -amino]phenyl}aery 1ic acid (105mg) . A mixture of the above 3 - { 2 - [ ( ( 2S ) - 5 - amino- 2 -{[(4-biphenylylamino)carbonyl]amino}pentanoyl)-amino]phenyl}acrylic acid (95mg, 0.2 Ommo1) and 1 0 % palladium on carbon (50% wet, l0mg) in MeOH ( 5mL) was hydrogenated at atmospheric pressure of hydrogen at room t empe rature. After 4 hours, the catalyst was removed by filtration and evaporated to give residue, which was dissolved in DCM (2 0mL) . To the resulting mixture was added 1- (benzyloxycarbonyloxy) -benzotriazole-6-carboxamidomethyl polystyrene (1.08g, 0.93mmole/g), and the mixture was shaken for 1 week at room temperature. The resin was removed by filtration and evaporation of the solvent gave a residue , which was purified by HPLC (reverse phase Ci8/ 5// , 3 0mm X 50mm column , 254nm, gradient 10-90% 0.1% TFA in CH3CN / 0.1% TFA in H2O, 40mL/min.) . The fractions containing the target compound were combined, evaporated, and dried under reduced pressure to give the target compound (12.4mg). MS ( (-)ESI) m/z : 607 (M-H)~. 2H-NMR (DMSO-d6) : 5 1 . 45- 2 . 05 ( 4H, m), 2 . 40 - 2 . 55 (2H, m), 2.81(2H, t, J=7.5Hz), 3.00-3.15(2H, m), 4 . 40-4 . 60 ( 1H, m) , 5.00(2H, s), 6.55(1H, d, J=7.6Hz), 7.10-7.65(19H,m), 8.81(1H, s) , 9.63(1H, S) , 12 . 17 (1H, br-s) . In order to illustrate the usefulness of the object Compound (I) , the pharmacological test is carried out as shown in the following-Test Example Binding assay using membrane preparation with the expression of prostanoid receptor subtype [I] Test Compound: Sodium 6-{ (2S) - 2 - [ (l-benzofuran-2-yl-carbonyl)-amino]-5-[benzyloxycarbonylamino]pentanoylamino}-hexanoate (Example 23) [II] Test Method: The membrane fraction was prepared using COS - 7 cells transfected prostanoid receptor subtype (human EP4 ) . The standard assay mixture contained membrane fraction, [3H]-PGE2 in final volume of 0.2 5mL was incubated for lhour at 30ºC . The reaction was terminated by that the mixture was rapidly filtered through a glass filter (GF/B) . Then the filter was washed with 4mL of ice-cooled buffer two times. The radioactivity associated with the filter was measured by liquid scintillation counting. In the experiment for competition of specific [3H]-PGE2 was added at a concentration of lOnM. The following buffer was used in all reactions. Buffer: 20mM Mes (pH 6.0), ImM EDTA, 10 mM MgCl2 The inhibition (%) of the compound at a concentration of lOnM was shown below. [Ill] Test Result: The test compound (1.0xlO~8M) showed the inhibition of 80% or more. It appeared, from the above-mentioned inhibition test, that Compound (I) or pharmaceutically acceptable salt thereof of the present invention binds to PGE2 receptor subtype, especially EP4, preferentially more than PGE2. Therefore, Compound (I) of the present invention has an activating or inhibiting activity of PGE2 receptor subtype. In consequence, Compound (I) or pharmaceutically acceptable salt thereof is useful for treating or preventing diseases mediated by PGE2f more particularly useful for treating or preventing kidney dysfunction (e.g., acute nephritic syndrome, recurrent or persistent hematuria, chronic nephritic syndrome, nephritic syndrome, rapidly progressive nephritic syndrome, acute renal failure, chronic renal failure), inflammation and pain in joint and muscle (e.g., rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, juvenile arthritis) , i n f1 amma tory skin condition (e.g., sunburn, burns, eczema, dermatitis) , infl animator y eye condition (e.g. , conjunctivitis) , lung disorder in which inflamma t i on is involved (e.g., asthma, bronchitis, pigeon fancier's disease, farmer's lung), condition of the gastrointestinal tract associated with inflamma t i on (e.g., aphthous ulcer, Chrohn's disease, atrophic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome), gingivitis, inflammat ion, nephrithis, pain and tumescence after operation or injury, pyrexia, pain and other conditions associated with inflammat ion, allergic disease, systemic lupus erythematosus, scleroderma, polymyositis, tendinitis, bursitis, periarteritis nodose, rheumatic fever, Sjgren's syndrome, Behcet disease, thyroiditis, type I diabetes, diabetic complication (e.g., diabetic microangiopathy, diabetic retinopathy, diabetic nephropathy), nephrotic syndrome, aplastic anemia, myasthenia gravis, uveitis, contact dermatitis, psoriasis, Kawasaki disease, sarcoidosis, Hodgkin ' s disease, Alzheimers disease, migraine, liver dysfunction (e.g., hepatitis, cirrhosis), gastrointestinal dysfunction (e.g., diarrhea, in f1 amma tory bowel diseases), shock, bone disease characterized by abnormal bone metabolism such as osteoporosis (especially, postmenopausal osteoporosis), hyper-calcemia, hyperparathyroidism, Paget1s bone diseases, osteolysis, hypercalcemia of malignancy with or without bone metastases, rheumatoid arthritis, periodontitis, osteoarthritis, ostealgia, osteopenia cancer, cancer cachexia, breast cancer, calculosis, lithiasis (especially, urolithiasis), solid caricinoma, neurodegenerative disorder, sleeping disorder, hyperaldosteronism sexual dysfunction, or the like in human being or animal. The Compound (I) of the present invention or its salts is also useful for the preparation of medicament having diuretic activity, which are useful for the preparation of drugs indicated treating or preventing various edema (e.g. cardiac edema, cerebral edema), hypertension such as malignant hypertension or the like, premenstrual tension, urinary calculus, oliguria such as the one caused by acute or chronic failure, hyperphosphaturia, or the like. CLAIMS 1. A compound of the formula (I) : wherein X is -CO- or -(CH2)k- (wherein k is 1, 2 or 3); y is (1) lower alkyl, or (2) Z-(CH2)n-, {whe rein Z is ( 1 ) a ryl, or (2 ) R1CO-NR4-(whe rein R1 is (1) ary1, heterocyclyl, ary1- (lower alkyl), ary1- (lower alkoxy,)or heterocyclyl- (lower alkoxy) , each of which may be substituted with one or more substituent ( s) selected from the group consisting of ( a) 1 owe r alkyl, ( b) ha1ogen and (c) hydroxy; or (2) lower alkoxy; and R4 is hydrogen, or lower alkyl); and n is 1 , 2, 3 , 4 , 5 or 6 } ; R2 is (1) lower alkyl, aryl- (lower alkyl) or (lower alkyl)thio- (lower alkyl), each of which may be substituted with one or more substituent(s) selected from the group consisting of (a) heterocyclyl, ( b) carboxy, (c) carboxy-(lower alkyl), (d) amidated carboxy, (e) (lower alkoxy)carbonyl which may be substituted with cycloalkyl, heterocyclyl or (lower alkanoyl)oxy; and (f) cyano; or (2) aryl which may be substituted with lower alkyl, lower alkenyl, aryl, lower alkoxy, (lower alkyl) amino, (lower alkyl)thio, carboxy, (lower alkoxy)carbonyl, (lower alkoxy)-(lower alkyl), (lower alkyl) ainino- (lower alkyl), or (lower alkyl) thio- (lower alkyl), each of which may be further substituted with one or more substituent (s) selected from the group consisting of (a) heterocyclyl, (b) (lower alkoxy)carbonyl, ( c) ca rboxy and (d) amidated carboxy; R3 is ( 1 ) -Q-R7 , [ whe rein Q is -CO- or -S02- , R7 is (a) lower alkyl which may be substituted with one or more substituent (s) selected from the group consisting of cycloalkyl, aryl which may be further substituted with ary1 (s) , and heterocyclyl, (b) lower alkenyl which may be substituted with one or more substituent (s) selected from the group consisting of aryl and heterocyclyl, (c) cycloalkyl, (d) aryl which may be substituted with one or more substituent (s) selected from the group consisting of 1 owe r alkyl, aryl which may be further substituted with hydroxy(s), 1owe r a1koxy, aryloxy, hydroxy, and halogen, (e) heterocyclyl which may be substituted with one or more subs tituent(s) selected from the group consisting of 1ower a1ky1, aryl which may be further substituted with halogen(s),and halogen, (f) aryloxy,or (g) amino which may be substituted with aryl (s) which may be further substituted with one or more substituent(s)selected from the group consisting of aryl and heterocyclyl]; o r (2) lower alkyl which may be substituted with aryl(s) or heterocyclyl(s), each of which may be further substituted with aryl (s) ; and R5 and R6 are independently hydrogen or lower alkyl; or R6 and Y may be linked together to form - (CH2)m- (wherein m is 2,3,4or5); or a pharmaceutica11y acceptable salt thereof. 2. A compound of claim 1 having the formula (la) : wherein Z , R2 , R7 and n are as defined above. 3. A compound of claim 1 having the formula (Ib) : wherein R1, R2, R7 and n are as defined above. 4. A compound of claim 3, whe rein R1 is aryl- (lower alkoxy); R2 is lower alky, or aryl which may be substituted with carboxy-(lower alkyl); R7 is heterocyclyl which may be substituted with substituted with lower alkyl; and n is 1,2, 3,4or5. 5. A compound selected from: sodium 6-{ (2S)-2-[ (l-benzofuran-2-yl-carbonyl) amino]-5-[benzyloxycarbonylamino]pentanoylamino}- hexanoate, (2E) -3-{2- [ (2S) -2- [ (lH-indol-2-ylcarbonyl)amino]-5 - [benzyloxycarbonylamino]pentanoylamino]phenyl}- acrylic acid, (2E)-3-{2-[ (2S) -2- [ (l-methyl-lH-indol-2-yl- carbonyl) amino]-5- [benzyloxycarbonylamino] - pentanoylamino]phenyl}acrylic acid, 3- { 2- [ (2S) -2- [ (l-methyl-lH-indol-2-ylcarbonyl) - amino]-5-[benzyloxycarbonylamino]pentanoylamino]- phenyl}propanoic acid, sodium 3 - {2 - [ (2S) -2-[ (2-quinolinylcarbonyl) amino] - 5- [benzyloxycarbonylamino]pentanoylamino]phenyl}- pr opano ate, 6- [ ( (2S) -2- [ (l-benzofuran-2-ylcarbonyl)amino] - 5 - { [ (benzyloxy) carbonyl]aminoJpentanoyl) amino] - 2 - naphthoic acid, 3- { 2- [ ( (2S)-5-{ [ (benzyloxy)carbonyl]amino}-2-{ [ (8-methylimidazo[1,2-a]pyridin-2-yl)carbonyl]aminojpentanoyl )amino]phenylJpropanoic acid, 3- [2- ( { (2S) -5-{ [ (benzyloxy) carbonyl] amino}-2-[ (2-quinolinylmethyl) amino]pentanoyl}amino) -phenyljpropanoic acid, and 3- [ 2- ( { (2S)-5-{ [ (benzyloxy)carbonyl]amino}-2-[ (1H-indol-2-ylcarbonyl)amino]pentanoyl}amino)phenyl]-propanoic acid. 6. A process for preparing the compound of the formula (Ia-1) : whe rein Y is (1) lower alkyl, or (2) Z- (CH2)n-, {whe rein Z is ( 1) aryl, or ( 2 ) R1CO-NR4-( wherein R1 is (1) aryl, heterocycly1, aryl- (lower alkyl), aryl- (lower a 1koxy) , or heterocyclyl- (lower alkoxy) , each of which may be substituted with one or more s ub s t i t u e n t ( s ) selected from the group consisting of (a) 1 owe r a1ky1, (b) halogen and (c) hydroxy; or (2) lower alkoxy; and R4 is hydrogen, or lower alkyl); and n is 1, 2 , 3, 4, 5 or 6 } ; Q is -CO- or -SO2- ; R2 is (1) lower alkyl, aryl- (lower alkyl) or (lower alkyl) thio- (lower alkyl), each of which may be substituted with one or more substituent(s) selected from the group consisting of (a) heterocyclyl, (b) carboxy, (c) carboxy-(lower alkyl), (d) amidated carboxy, (e) (lower alkoxy)carbonyl which may be substituted with cycloalkyl, heterocyclyl or (lower alkanoyl)oxy; and (f) cyano; or (2) aryl which may be substituted with lower alkyl, lower alkenyl, aryl, lower alkoxy, (lower alkyl)amino, (lower alkyl)thio, carboxy, (lower alkoxy)carbonyl, (lower alkoxy)-(lower alkyl), (lower alkyl) amino- (lower alkyl), or (lower alkyl) thio- (lower alkyl), each of which may be further substituted with one or more substituent(s) selected from the group consisting of (a) heterocyclyl, (b) (lower alkoxy)carbonyl, (c) carboxy and (d) amidated carboxy; R5 and R6 are independently hydrogen or lower alkyl; or R6 and Y m a y be linked together to form - (CH2)m- (wherein m is 2 , 3 , 4 or 5); and R7 is (a) lower alkyl which may be substituted with one or more substituent(s) selected from the group consisting of cycloalkyl, aryl which may be further substituted with ary1(s) , and heterocyclyl , (b) lower alkenyl which may be substituted with one or more substituent (s) selected from the group consisting of aryl and heterocyclyl, (c) cycloalkyl, (d) aryl which may be substituted with one or more substituent (s) selected from the group consisting of 1 owe r alkyl, aryl which may be further substituted with hydroxy(s), 1 owe r alkoxy, ar y1oxy, hydroxy, and halogen, (e) heterocyclyl which may be substituted with one or more s ub s t i t uen t ( s ) selected from the group consisting of 1 owe r alkvl, aryl which may be further substituted with halogen(s), and halogen, (f) aryloxy, or (g) amino which may be substituted with aryl(s) which may be substituted with one or more substituent(s) selected from the group consisting of aryl and heterocyclyl]; or a pharmaceutically acceptable salt thereof, comprising, reacting a compound (Ila) : (wherein Y and R6 are each as defined above), or its reactive derivative at the carboxy group or the salt thereof, with a compound (IlIa) : (wherein R2 and R5 are each as defined above), or its reactive derivative at the amino group or the salt thereof to give a compound (IVa): (wherein Y, R2, R5 and R6 are each as defined above), or its salt; and reacting the compound (IVa): (wherein Y, R2, R5 and R6 are each as defined above), or its salt, with a compound (V): (wherein Q and R7 are each as defined above), or its reactive derivative at the carboxy group (in case of Q is -CO-) /the sulfo group (in case of Q is -SO2-) ,or the salt thereof. 7. A process for preparing the compound of the formula (Ib-1 ) : whe rein X is -CO-, or -(CH2)k- (wherein k is 1, 2 or 3); Q is -CO- or -S02-; R1is (1)ary1, heterocyclyl, aryl- (lower alkyl), aryl- (lower alkoxy),or heterocyclyl- (lower alkoxy), each of which may be substituted with one or more substituent(s) selected from the group consisting of (a) 1 owe r a1ky1, (b) halogen and (c) hydroxy; or (2) lower alkoxy; and R2 is (1) lower alkyl, aryl- (lower alkyl) or (lower alkyl) thio- (lower alkyl), each of which may be substituted with one or more substituent(s) selected from the group consisting of (a) heterocyclyl, (b) carboxy, (c) carboxy- (lower alkyl), (d) amidated carboxy, (e) (lower alkoxy)carbonyl which may be substituted with cycloalkyl, heterocyclyl or (lower alkanoyl)oxy; and (f) cyano; or (2) aryl which may be substituted with lower alkyl, lower alkenyl, aryl, lower alkoxy, (lower alkyl)amino, (lower alkyl)thio, carboxy, (lower alkoxy)carbonyl, (lower alkoxy)-(lower alkyl), (lower alkyl)amino-(lower alkyl), or (lower alkyl) thio- (lower alkyl), each of which may be further substituted with one or more substituent(s) selected from the group consisting of (a) heterocyclyl, (b) (lower alkoxy)carbonyl, (c) carboxy and (d) amidated carboxy; R5 and R6 are independently hydrogen or lower alkyl; or R6 and Ymay be linked together to form - (CH2)m- (wherein m is 2, 3, 4 or 5) ; R1 is (a) lower alkyl which may be substituted with one or more subs t i tuent ( s ) selected from the group consisting of cycloa1ky1, aryl which may be further substituted with aryl(s), and heterocyclyl, (b) lower alkenyl which may be substituted with one or more substituent(s) selected from the group consisting of aryl and heterocyclyl, (c) cycloa1ky1 , (d) aryl which may be substituted with one or more substituent(s) selected from the group con sisting of lower alkyl, aryl which may be further substituted with hydroxy{ s ) , lower alkoxy, aryloxy, hydroxy, and halogen, (e) heterocyclyl which may be substituted with one or more substituent(s) selected from the group consisti ng of 1ower alkyl, aryl which may be further substituted with ha logen(s) , and halogen, (f) aryloxy, or (g) amino which may be substituted with aryl(s) which may be substituted with one or more substituent(s) selected from the group consisting of aryl and heterocyclyl]; and n is 1 , 2, 3, 4 , 5 or 6; or a pharmaceutically acceptable salt thereof, comprising, reacting a compound (lIb): (wherein X, R2, R5, R6 and n are each as defined above) , or its reactive derivative at the amino group or the salt thereof, with a compound (IIIb): (wherein R1 is as defined above), or its reactive derivative at the carboxy group or the salt thereof to give a compound (IVb): (wherein X, R1, R2, R5, R6, n and are as defined above), or its salt; and reacting the compound (IVb): (wherein X, R1, R2, R 5, R6 and n are as defined above), or its salt, with a compound (V): Rl ,OU Q (V) (wherein Q and R7 are as defined above) , or its reactive derivative at the carboxy group (in case of Q is -CO-) /the sulfo group (in case of Q is - SO2- ) , o r the salt thereof. 8 . A process for preparing the compound of the formula ( Ia-2) : whe rein Y is (1) lower alkyl,or (2) Z-(CH2)n-, {wherein Z is ( 1 ) ary1, or (2 ) R1CO-NR4-(wherein R1 is (1) aryl, heterocyclyl, aryl- (lower alkyl), aryl- (lower alkoxy), or heterocyclyl- (lower alkoxy) , each of which may be substituted with one or more substituent(s) selected from the group consisting o f ( a) 1 owe r alkyl, (b) halogen and (c) hydroxy; or (2) lower alkoxy; and R4 is hydrogen, or lower alkyl); and n is 1, 2 , 3, 4 , 5 or 6 } ; Q is -CO- or - S02- ; R2'is (1) lower alkyl, (loweralkyl)thio-(lower alkyl) or aryl-(lower alkyl); or (2) aryl which may be substituted with lower alkyl, lower alkenyl, aryl, lower alkoxy, (lower alkyl)amino, (lower alkyl)thio, (lower alkoxy)-(lower alkyl), (lower alkyl) amino- (lower alkyl), or [(lower alkyl)thio]-(lower alkyl); R6 is hydrogen or lower alkyl; or R6 and Y may be linked together to form - (CH2)m- (m is 2 , 3, 4 or 5) ; R7 is (a) lower alkyl which may be substituted with one or more substituent (s) selected from the group consisting of cycloa1ky1, aryl which may be further substituted with aryl(s), and heterocyclyl, (b) lower alkenyl which may be substituted with one or more s ubs t i t uent ( s ) selected from the group consisting of aryl and heterocyclyl, (c) cyc1oa1ky1, (d) aryl which may be substituted with one or more substituent (s) selected from the group consisting of lower alkyl, aryl which may be further substituted with hydroxy(s), lower alkoxy, a ry1 ox y, hydroxy, and halogen, (e) heterocyclyl which may be substituted with one or more substituent (s) selected from the group consisting of 1 owe r alkyl, aryl which may be further substituted with halogen (s) , and halogen, (f) aryloxy, or (g) amino which may be substituted with aryl(s) which may be substituted with one or more substituent(s) selected from the group consisting of aryl and heterocyclyl]; or a pharmaceutically acceptable salt thereof, comprising, reacting a compound (Ila) : (wherein Y and R6 are each as defined above), or its reactive derivative at the carboxy group or the salt thereof, with a resin-bound compound (IIIc) : (wherein R2' is as defined above, and P is polymer), or its reactive derivative at the amino group or the salt thereof to give a compound (IVc): (wherein Y, P R2' and R6 are as defined above), or its salt; reacting the compound (IVc) : (wherein Y,P R2' and R6 are as defined above), or its salt, with a compound (V) : (wherein Q and R7 are as defined above) , or its reactive derivative at the carboxy group (in case of Q is -CO- ) /the sulfo group (in case of Q is -SO2-)/ or the salt thereof to give a compound (Ia-2' ) : (wherein Q , Y , P, R2', R6, and R7 are as defined above), or its salt; and subjecting the compound (Ia-2'): (wherein Q, Y, P , R2' , R6, and R7 are as defined above), or its salt to a cleavage reaction of the resin. 9 . A compound of any one of Claims 1 to 5 for use as a medicament. 10. The compound of Claim 9 for use in the treatment and/or prevention of PGE2 mediated diseases in human beings or animals. 11. A medicament comprising a compound of any one of Claims 1 to 5 as an active ingredient. 12. A pharmaceutical composition comprising a compound of any one of Claims 1 to 5 as an active ingredient, in association with a pharmaceutically acceptable carrier or excipient. 13. An agonist or antagonist of PGE2 consisting of a compound of any one of Claims 1 to 5. 14. A method for treatment and/or prevention of PGE2 mediated diseases which comprises administering an effective amount of the compound of any one of Claims 1 to 5 to human beings or animals. 15. A method for treating or preventing kidney dysfunction, inflammatory conditions, various pains, collagen diseases, autoimmune diseases, various immun ity diseases, analgesic, thrombosis, allergic disease, cancer or neurodegenerative diseases which comprises a dministering an effective amount of a compound of any one of Claims 1 to 5 to human beings or an ima1s . 16. Use of a compound of any one of Claims 1 to 5 as ! ' I ' - a medi cament. 17. Use of a compound of any one of Claims 1 to 5 as an agonist or an antagonist of PGE2-sensitive receptor. 18. Use of the compound of any one of Claims 1 to 5 for treatment andor prevention of PGE2 mediated diseases in human beings or animals. 19. A comme rcial package comprising the pharmaceutical composition containing the compound identified in any one of any one of Claims 1 to 5 and a written matter associated therewith, wherein the written matter states that the compound (I) can or should be used for preventing or treating PGE2 mediated diseases. Dated this 21 day of July 2006